Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

9-27-2013

Bionano Electronics: Magneto-Electric
Nanoparticles for Drug Delivery, Brain Stimulation
and Imaging Applications
Rakesh Guduru
rgudu001@fiu.edu

DOI: 10.25148/etd.FI13112201
Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Bioelectrical and Neuroengineering Commons, Biomaterials Commons, Biomedical
Commons, Computational Engineering Commons, Nanotechnology Fabrication Commons, and
the Other Biomedical Engineering and Bioengineering Commons
Recommended Citation
Guduru, Rakesh, "Bionano Electronics: Magneto-Electric Nanoparticles for Drug Delivery, Brain Stimulation and Imaging
Applications" (2013). FIU Electronic Theses and Dissertations. 979.
https://digitalcommons.fiu.edu/etd/979

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

BIONANO ELECTRONICS: MAGNETO-ELECTRIC NANOPARTICLES FOR
DRUG DELIVERY, BRAIN STIMULATION AND IMAGING APPLICATIONS

A dissertation submitted in partial fulfillment of the
requirements for the degree of
DOCTOR OF PHILOSOPHY
in
ELECTRICAL ENGINEERING
by
Rakesh Guduru

2013

To: Dean Amir Mirmiran
College of Engineering and Computing
This dissertation, written by Rakesh Guduru, and entitled Bionano Electronics: MagnetoElectric Nanoparticles for Drug Delivery, Brain Stimulation and Imaging Applications,
having been approved in respect to style and intellectual content, is referred to you for
judgment.
We have read this dissertation and recommend that it be approved.
_________________________________
Madhavan Nair

_________________________________
Osama A. Mohammed

_________________________________
Jean H. Andrian

_________________________________
Jeffrey Fan
_________________________________
Sakhrat Khizroev, Major Professor
Date of Defense: September 27, 2013
The dissertation of Rakesh Guduru is approved. _________________________________
Dean Amir Mirmiran
College of Engineering and Computing

_________________________________
Dean Lakshmi N. Reddi
University Graduate School

Florida International University, 2013

ii

DEDICATION
I would like to dedicate this dissertation to my family and friends. Their love and
support has been the driving force of my life.

iii

ACKNOWLEDGMENTS
This dissertation was only possible due to the continuous support from my mentor, family
and friends. I would like to specially thank my wife Pallavi Joshi for showing
unconditional love and support throughout my Ph.D. I also would like to express my
gratitude towards my mentor Dr. Sakhrat Khizroev for providing 24X7 guidance
throughout my research and constantly encouraging me to perform groundbreaking
research. I can never imagine completing my Ph.D. without his valuable advises and
continuous support. I would also like to thank our collaborator Dr. Madhavan Nair for
providing valuable guidance in this cross-disciplinary (Immunology & Electrical
engineering) research. I would further like to extend my thanks to Dr. Jeongmin Hong for
helping me in various aspects of my research.

iv

ABSTRACT OF THE DISSERTATION
BIONANO ELECTRONICS: MAGNETO-ELECTRIC NANOPARTICLES FOR
DRUG DELIVERY, BRAIN STIMULATION AND IMAGING APPLICATIONS
by
Rakesh Guduru
Florida International University, 2013
Professor Sakhrat Khizroev, Major Professor
Nanoparticles are often considered as efficient drug delivery vehicles for precisely
dispensing the therapeutic payloads specifically to the diseased sites in the patient’s body,
thereby minimizing the toxic side effects of the payloads on the healthy tissue. However,
the fundamental physics that underlies the nanoparticles’ intrinsic interaction with the
surrounding cells is inadequately elucidated. The ability of the nanoparticles to precisely
control the release of its payloads externally (on-demand) without depending on the
physiological conditions of the target sites has the potential to enable patient- and
disease-specific nanomedicine, also known as Personalized NanoMedicine (PNM). In
this dissertation, magneto-electric nanoparticles (MENs) were utilized for the first time to
enable important functions, such as (i) field-controlled high-efficacy dissipation-free
targeted drug delivery system and on-demand release at the sub-cellular level, (ii) noninvasive energy-efficient stimulation of deep brain tissue at body temperature, and (iii) a
high-sensitivity contrasting agent to map the neuronal activity in the brain noninvasively. First, this dissertation specifically focuses on using MENs as energy-efficient
and dissipation-free field-controlled nano-vehicle for targeted delivery and on-demand
release of a anti-cancer Paclitaxel (Taxol) drug and a anti-HIV AZT 5’-triphosphate

v

(AZTTP) drug from 30-nm MENs (CoFe2O4-BaTiO3) by applying low-energy DC and
low-frequency (below 1000 Hz) AC fields to separate the functions of delivery and
release, respectively. Second, this dissertation focuses on the use of MENs to noninvasively stimulate the deep brain neuronal activity via application of a low energy and
low frequency external magnetic field to activate intrinsic electric dipoles at the cellular
level through numerical simulations. Third, this dissertation describes the use of MENs to
track the neuronal activities in the brain (non-invasively) using a magnetic resonance and
a magnetic nanoparticle imaging by monitoring the changes in the magnetization of the
MENs surrounding the neuronal tissue under different states.
The potential therapeutic and diagnostic impact of this innovative and novel study
is highly significant not only in HIV-AIDS, Cancer, Parkinson’s and Alzheimer’s disease
but also in many CNS and other diseases, where the ability to remotely control targeted
drug delivery/release, and diagnostics is the key.
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1. Chapter 1: Introduction
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1.1. Motivation
The majority of the current nanoparticle based drug delivery systems are inefficient due
to their dependence on the intrinsic properties of the cell/tissue physiological conditions
to dispense cargo, thereby reducing the bioavailability of the therapeutic drugs. The
primary motivation of the dissertation was to develop an energy-efficient drug delivery
system that could release ~ 100% of the therapeutic drug on-demand using the low field
and low frequency remote magnetic field. The secondary motivation of the dissertation
was to develop a non-invasive deep brain stimulation method to treat neurological
disorders, such as Parkinson’s, Alzheimer’s, dementia, etc. Currently, the most widely
used method is deep brain stimulation (DBS) that uses an extremely invasive direct
contact electrode to stimulate the dysfunctional neurons in the deep brain region. Another
goal of the dissertation was to develop a contrasting agent for magnetic resonance
imaging and magnetic nanoparticle imaging to map neuronal activities of the brain
(irrespective of its origin, i.e. superficial or deep tissue). Currently used techniques
(electroencephalogram and magnetoencephalogram) can only record the neuronal
activities in the superficial tissue (cortex) but not in the deep brain tissues.
1.2. Specific aims
Specific Aim 1: To develop an energy-efficient drug delivery vehicle that could release
close to a 100 % of the bound therapeutic payload on-demand using externally controlled
remote magnetic fields.
Most of the current nanoparticle based drug delivery methods (both targeted and nontargeted) rely on the physiological conditions of the cell, such as temperature, redox, pH,
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enzymatic reactions, etc. to release the therapeutic payloads. As a result, the drug
releasing process is extremely inefficient due to the dependence on the minute changes in
the physiological conditions in the microenvironment of the cell. Conversely, the MENsbased drug delivery method, which has been proposed by our research team, is
independent of physiological conditions, as the drug-releasing process can be completely
controlled using external magnetic fields. Similar to the conventional magnetic
nanoparticle (MN), the MEN have a non-zero magnetic moment and therefore can be
controllably transported through a body via application of a remote magnetic field
gradient. However, unlike the MN, the MEN display an entirely new property, which is
the non-zero magneto-electric (ME) effect. The origin of this effect is the intrinsic
coupling between electric and magnetic fields within the MEN, even at body temperature.
Because of its quantum-mechanical nature, the coupling is extremely energy efficient and
can be made dissipation free. Moreover, these payloads are steered to the site of delivery
using external magnetic fields, thereby increasing the bioavailability of the drugs. This
technology was evaluated on the two most researched areas, i.e. neurological-HIV and
ovarian cancer, to deliver therapeutic drugs on-demand.

Specific Aim 2: To surface-functionalize the MENs for carrying a wide range of
therapeutic drugs to treat multiple diseases and to maximize the payload carrying
capacity.
Therapeutic drugs are attached to the nano-vehicles via covalent, non-covalent
(electrostatic, Van der Waal, hydrogen), or ionic bonds. Modifying the surface properties
(i.e. by controlling the surface charge and polarity) of the nano-vehicle could assist in
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attaching a wide range of therapeutic drugs on the surface. This is a key requirement for
applying the technology to treat numerous diseases. Surface properties of the nanovehicles are altered using several functionalizing agents. Tailoring the surface properties
of nano-vehicles not only enables them to carry wide varieties of payloads, but could also
improve the payload carrying capacity and drug-binding efficacy.

Specific Aim 3: To develop a non-invasive neuronal stimulation method to restore the
neuronal activity of the dysfunctional neurons using a low field and low frequency
external magnetic field.
The signaling in a biological neuronal network is based on a highly collective system of
electric charges, neurotransmitters and action potentials. The ability to incite the neuronal
charge excitations from outside the body non-invasively with the purpose to artificially
stimulate the neuronal network remains an important roadblock to enabling leapfrog
advances in the important area of neuroscience and related applications in medicine and
neural engineering. One potential solution to overcome this important roadblock for
enabling the non-invasive control of the neuronal network is to exploit the magnetoelectric property of the MENs.

Specific Aim 4: To develop a new contrasting agent for imaging modalities (magnetic
resonance imaging, MRI and magnetic nanoparticle imaging, MNI) that could not only
act as a contrast enhancement agent, but could also provide the molecular information of
the cell/tissue microenvironment.
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The signal in the imaging modalities (MRI and MNI) is mainly dependent on the
magnetic saturation and the density of the contrasting agent. On the contrary, in MENs
(as contrasting agent), due to the intrinsic magnetic-electric coupling at the human body
temperature, the MRI signal also depends on electric fields that are involved in the
molecular bonding between the MENs and the surrounding environment. Additionally,
as the molecular bonds also control the fate of the MENs payloads, it could be possible to
visualize the dynamic drug release process in vivo. Moreover, these particles could also
give us information about electrical activity in the brain, as neuronal firing changes the
surface charge of the MEN due to the generation of action potential.
1.3. Nanomaterials for payload delivery, targeted therapy and diagnostics
Researchers have long been struggling to find a better way to dispense the therapeutic
payloads to the diseased tissues with high efficiency, precision, solubility, and stability
while maximizing the biodistribution/bioavailability of the therapeutic payloads. Paul
Ehrlich was the first person to propose the use of a delivery vehicle that could selectively
target the diseased-tissue/organism and deliver a toxin for that specific disease/organism.
Thus, the term “magic bullet” was coined to deliver the therapeutic payloads to a specific
location or to destroy an organism exclusively. Recently, several nanomaterials with
various compositions and biological properties have been designed to carry therapeutic
drug payloads to the target sites (2-6). These nanomaterials have unique advantages over
the conventional delivery systems, for example: (i) delivering the payloads to specific
locations in the body; (ii) minimizing the drug dose levels, as the drugs are delivered
right at the target site; and (iii) minimizing the drug levels at non-target sites, thereby
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reducing the toxic side effects. Besides the drug-delivery applications, nanomaterials are
also widely used for several other applications, such as cell imaging, diagnostics, protein
and nucleic acid (DNA/RNA) detection. Most widely used nanomaterials for drugdelivery and diagnostic applications include: Au nanoparticles, iron oxide nanoparticles,
magneto-electric nanoparticles, Poly(lactic-co-glycolic acid) nanoparticles, carbon
nanotubes, and mesoporous silica nanoparticles. Drug delivery and diagnostic
applications using some of these nanomaterials are elaborated in detail in the following
section.
1.3.1.

Gold nanoparticles

First, gold nanoparticles (AuNPs) are used widely to delivery a wide range of payloads
(including proteins, nucleic acids (DNA & RNA), small and large drug molecules) to the
target sites (7-13). The release of the payloads using AuNPs can be controlled using a
micro-environmental physiological stimulus of the cell (pH or glutathione-mediated) or
an external stimulus (light or temperature) (12, 14-17), as shown in Figure 1A. Second,
AuNPs are used in enhancing the dose amounts of low-energy x-rays and gamma rays
(<100 KeV), which appears to be a highly feasible and alternative approach to fulfill
some technical and clinical limitations for eradicating tumors requiring higher dose levels
(18). Third, AuNPs are used in photothermal therapy of cancer (19, 20). Here, AuNPs are
accumulated at the tumor tissues and irradiated with an external laser source (650-900
nm). Due to the strong electric fields at the surface of the noble metal, the absorption and
scattering of the electromagnetic radiation is greatly enhanced, thus producing the heat to
eradicate the surrounding tumor cells. The specificity of the photothermal therapy, i.e. to
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target only tumor tissues, is achieved by tagging the AuNPs with HER-2 antibodies,
which now specifically bind only to the tumor cells (21, 22). Fourth, AuNPs are also used
in cancer cell imaging (23). Epidermal growth factor receptors (EGFR) conjugated
AuNPs are employed to bind specifically to human oral squamous cell carcinoma (HSC
and HOC). Such cells, when irradiated with near-infrared light, produce strong absorption
and scattering. The emitted radiation is captured using light scattering and surface
plasmon resonant absorption spectroscope to produce an image specific to carcinomas
(shown in Figure 1B).

Figure 1: A) AuNPs for delivering the therapeutic agents. a) bare-AuNPs, b) AuNPs loaded with therapeutic
agents (proteins/DNA/RNA/drugs), c) encapsulation of AuNPs loaded with therapeutic agents, and d) release of
therapeutic agents by the physiological (pH and temperature) and external stimulations (light). Figure 1B, a)
cancer cell surface with biomarkers, b) AuNPs, tagged with anti-biomarkers, c) accumulations of biomarker
tagged-AuNPs on cancer cell surface, and d) a surface plasmon resonant absorption spectroscope image showing
only cancer cells through AuNPs accumulation.
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All of the above described delivery and therapeutic applications of AuNPs are possible
because of the unique chemical and physical properties of the gold metal. Moreover, the
ease of fabrication techniques to synthesize uniform AuNPs of different sizes (1 to 150
nm) and shapes (cubes, spheres and rods) lead to their use in multiple clinical
applications (24-27). Further, AuNPs are also inert and non-toxic in nature, which makes
it possible to employ them, as drug delivery vehicles in human and animal subjects with
no toxic side effects (28-32).


Advantages of AuNPs
a. Biocompatibility: AuNPs show less or no toxicities in the in-vitro and invivo applications.
b. Ease of fabrication: chemical synthesis of AuNPs of different sizes and
shapes is extremely simple.
c. Ease of tailoring surface properties: ability to functionalize the
nanoparticles to carry a wide range of therapeutic payloads is mandatory
in treating a wide range of diseases.
d. Eradication of radiation-resistant tumors: enhancement of low energy xrays and gamma rays to eradicate radiation resistant carcinomas.
e. Diagnostics: tumor detection based on the cell-specific biomarkers.



Disadvantages of AuNPs
a. Inefficient release: The primary disadvantage of using AuNPs for payload
delivery is their dependence on micro-environmental physiological
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conditions of the cell as a stimulus, resulting in the drug release process
being extremely inefficient.
b.

Low penetration depths of visible light: the tissue penetration depth is a
huge limitation in treating deep-tissue carcinomas. (Note: The visible light
tissue penetration depth is only 2-3 cm).

c. Antibody tagging: targeted delivery is completely driven by the cellspecific antigen and antibody reactions, thereby limiting its application
only to the biomarker specific targets.
d. Specificity: use of AuNPs, as contrasting agents also demands surface
functionalization of the nanoparticles with cell-specific antibodies. Thus, only
the carcinomas carrying the counter antibodies (or antigen) can be detected.

Note: AuNPs for biomedical applications and their fundamental limitations are
summarized in Figure 2.
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Figure 2: Advantages and disadvantages of AuNPs in various biomedical applications.

1.3.2. Iron oxide nanoparticles
The use of iron oxide (γ-Fe2O3 or Fe3O4) particles for in vitro medical diagnostics
applications has been practiced for more than 50 years (33). However, over the last
decade, the use of nanosized iron oxide particles, especially Fe3O4 (magnetite) has
become extremely popular due to their ability to function at the molecular level, having
distinctive physical properties, and for showing biocompatibility (34-36). The unique
physical properties, i.e. quantum-size and large surface area of the magnetite dramatically
change its magnetic properties, to exhibit quantum tunneling and superparamagnetism.
These unique properties offer high potential for numerous biomedical applications, such
as cell labeling cell isolation, payload delivery, tissue repair, MR contrast enhancement,
and hyperthermia. Surface functionalized magnetite nanoparticles could be dispersed into
appropriate solvents to form homogeneous ferrofluids (37, 38). To perform therapeutic
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procedures, these ferrofluids can be steered to any part of the subject’s body
(human/animal) using an external magnetic field gradient system (39-41). Intravenous
administration of ferrofluids is relatively non-toxic and such preparations are used in
current clinical applications (42).

The main advantages of using magnetic nanoparticles (MNs) over the non-magnetic
particles includes: (i) MNs can be visualized using MRI and MNI modalities, thus
ensuring that the payloads are delivered to the right target sites; (ii) MNs can be
steered/positioned at any location in the body with a micrometer scale precision using an
external magnetic field gradient system, thus eliminating the dependence on cell-specific
antigen-antibody reactions; and (iii) The temperature of the MNs can be increased using
the

high frequency magnetic fields. The radiated heat can assist in releasing the

therapeutic drug and/or in ablation of the surrounding tissues (for example cancer tissue).
Various biomedical applications of the MNs are discussed in detail in the following
section.



Cellular labeling and cell isolation

Antibody tagged MNs are up-taken by the desired cells through cell-specific antigenantibody reaction or receptor mediated endocytosis or phagocytosis (43-45). The uptaken cells are imaged using MR/MN image modalities for their specific location in the
body. Desired cells can be isolated from the biological fluids by incubating with
antibody-coated magnetic beads. The desired cells are attached to the magnetic beads
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through cell-specific antigen-antibody reaction. Washing the cell-labeled magnetic beads
several times on magnetic racks isolates the desired cells.


Tissue repair

Synthetic-polymer/protein-coated MNs are used in the tissue repair procedure (46).
Briefly in this technique, two opposing tissues coated with nanoparticles are heated to 50
°C using a soldering gun or a laser source to seam them together (47). This technique
greatly minimizes the tissue damage, as it requires low temperatures and low energy laser
sources. The technique has a great potential to repair/transplant the desired tissues using
the stem cell payloads (48). Stem cells are specialized cells having a unique ability to
self-renew and differentiate into any other cell type. Stem cell-loaded MNs could be
navigated to the specific locations (damaged tissue) to perform the tissue
development/repair process. This type of technology has tremendous potential to treat
diseases, such as Alzheimer’s, Parkinson’s, and heart disease non-invasively.


Payload delivery

Like AuNPs, MNs can also carry a wide range of therapeutic payloads (drugs, proteins,
nucleic acids) to the target sites (49-51). To enable this, size, charge, and surface
chemistry of the MNs need to be tailored. For example, to conjugate the protein payloads
with the MNs, the surface of the nanoparticle is modified with poly ethylene glycol
(PEG) (52). These PEG modified MNs will also further benefit from being unrecognized
by the reticuloendothelial clearance system thus facilitating the tissue specific uptakes.
Moreover, surface modification using biodegradable materials (such as poly(lactic-co-
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glycolic acid)) also reduces the toxicity and immunological responses

to inorganic

material (such as MNs) (53, 54).


Magnetic resonance imaging

Superparamagnetic iron oxide nanoparticles (SPIONPs) are used, as a contrast
enhancement agent in MR imaging modality to better differentiate the pathological tissue
from the healthy tissue. SPIONPs are also capable of achieving near-microscopic
resolution in in-vivo MR imaging applications (55). MNs tagged with stem cells can be
visualized and tracked in the body using MR imaging (56). Further, stem cell tagged
MNs will not affect the growth, differentiation, viability, and proliferation of the attached
cell. SPIONPs are also used in visualizing the transgene expression and in detecting cell
apoptosis through MR imaging (57, 58).



Hyperthermia

The use of hyperthermia (heat) to eradicate the cancer cells is, as old as medicine itself.
Hippocrates first proposed the use of hot iron to burn the surface of carcinomas to
eradicate the diseased tissue. Currently, more advanced methods, such as perfusion
heating, ferrofluid hyperthermia, irreversible electroporation, and high-frequency
radiation are being used to heat, denature, and destroy the cancer cells (59-61). MNs can
also be used to generate substantial amount of heat to destroy tumors using the high
frequency magnetic fields (62, 63). The amount of heat generated using this phenomenon
(due to the hysteresis loss) depends on the material properties of the particles and also on
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the strength of the applied magnetic field and frequency. The applications of MNs and
their advantages and disadvantages are shown in Figure 3.

Figure 3: shows advantages and disadvantages of using magnetic nanoparticles for various applications.

Current state-of the-art MNs based technology for delivering anti-cancerous drugs or for
ablating tumor tissues (through hyperthermia) can only be applicable to a well-defined
tumor. However, treating small-tumors and metastatic neoplasms with this technology
still remains a challenge. Finally, MNs based technology can play a major role in treating
tumors in the regions, where conventional surgery methods cannot be applied.
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1.3.3. Magneto-electric nanoparticles
Any material that exhibits a strong quantum coupling of magnetic and electric properties
is generally called as magneto-electric material. These materials come under the
multiferroic category, as they simultaneously demonstrate both ferroelectric and
ferromagnetic properties (64). Figure 4 shows the relationship between the magnetoelectric and multiferroic materials. Borocite (Ni3B7O13I) was the first material reported to
exhibit magneto-electric switching below 60 K (65). Magnetic to electric energy
conversion exploits the advantages of properties from two different phases of the
material, i.e. from the ferromagnetic phase, piezomagnetic or magnetostrictive property
and from the ferroelectric phase, piezoelectric or electrostrictive property. Thus, when an
external magnetic field (ΔH) is applied, magnetostrictive stress formed in the magnetic
phase is transferred to the ferroelectric phase changing the polarization (ΔP) and the
associated electric field (ΔE) due to the piezoelectric effect. Performance of multiferroic
materials is determined by this transfer efficiency, which is called as magneto-electric
coefficient (α = ΔP / ΔH) or as magneto-electric voltage coefficient (αE = ΔE / ΔH).
Magneto-electric coefficients of various multiferroic materials are shown in Table 1.
Electric flux density (D) in multiferroic materials (Equation(1) is determined by the
magneto-electric coefficient tensor (αij), permittivity tensor (εij), and the piezoelectric
coefficients (eij) in an applied vector magnetic, electric field, and external stress S (64).
𝐷𝐷    =   




ε𝑖𝑖𝑖𝑖 𝐸𝐸 +
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𝑒𝑒𝑖𝑖𝑖𝑖 𝑆𝑆 +   




α𝑖𝑖𝑖𝑖 𝐻𝐻

(1)

Figure 4: The relationship between the magneto-electric and multiferroic materials.

Table 1: Magneto-electric coefficients in two-phase systems. (Note: BaTiO3 and Pb(Zr,Ti)O3 (PTZ) are
piezoelectric materials, and TbxDy1-xFe2 (terfenol-D), ferrites, and manganite are magnetostrictive materials.
ME coefficient, mV cm-1 Oe-1).

Ref.

BaTiO3 and CoFe2O4
Terfenol-D and PZT in polymer matrix
Terfenol-D and PZT/PZT (in polymer matrix)

ME
coefficient
50
42
3000

Terfenol-D/PZT
La0.7Sr0.3MnO3/PZT
NiFe2O4/PZT

4800
60
1,400

(69)
(70)
(70)

Morphology

Materials

Composite
Composite
Laminatedcomposites
Laminate
Laminate
Laminates

(66)
(67)
(68)

Multiferroic materials can be used in two forms, i.e. either in the laminate form or in the
particulate form. However, using multiferroic materials in the particulate form provides
excellent magneto-electric properties due to the below reasons:
a. Shape effects: spherical shape of the particles provides better transfer of
magnetostrictive stress from magnetic phase to the ferroelectric phase.
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b. Zero-substrate clamping effect: laminates/films needs to be clamped,
which restricts the magnetostrictive strains.
c. Binding efficiency: mechanical contact in the interface of particulate
composites is much higher as compared to the laminate/films composites.
(Note: laminate/films composites need to be either glued or sintered which
often results in poor binding efficacies).

So far, multiferroic materials are extensively used in microwave filters, signal
amplification devices, data storage devices, transducers, optical-diodes, power generation
systems, high frequency switches, miniature-antennas and spintronics (71-77), but for the
first time in this dissertation, we presented the biomedical applications of the multiferroic
materials (Note: details of these applications are provided in the next chapters). Unique
advantages of multiferroic materials for biomedical applications are discussed in detail in
the following sections.

1.4. Artificial brain stimulation for treating neurological disorders
The signaling in a biological neural network is based on a highly collective system of
electric charges, neurotransmitters and action potentials. The ability to incite the neuronal
charge excitations from outside with the purpose of artificially stimulating the neural
network remotely (non-invasively) remains an important roadblock to enable significant
advances in the important areas of neuroscience and related applications in medicine and
neural engineering. The progress of the existing invasive and non-invasive technologies,
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such as deep brain stimulation (DBS), transcranial magnetic stimulations (TMS),
repetitive transcranial magnetic stimulation (rTMS), and transcranial direct current
stimulation (tDCS) are discussed in detail in the following sections along with their
advantages and disadvantages.

1.4.1. Invasive stimulation
Invasive brain stimulation methods are currently being practiced for curing multiple
neurological disorders, such as Parkinson’s disease, neuropathic pains, major depression,
Alzheimer’s disease, Tourette syndrome, Epilepsy, Dystonia, obsessive-compulsive
disorders, tremors, and self-injury syndromes. These invasive brain stimulation methods
include: deep brain stimulation (DBS), thalamotomy, bilateral lesions, and pallidotomy.
Most of these techniques (except the DBS) are nearly discontinued due to their
irreversible complications and curtail therapeutic effects (78, 79). Currently, the only
practiced neurosurgical method for brain stimulation is DBS. In this technique,
programmable neuropacemakers (pulse generators) are connected to the implants
(electrodes), which are chronically inserted into the desired regions of the brain to
artificially restore its neural activity by periodic electric stimulation. Implants are held in
a desired location for weeks to years to stimulate the region of brain depending on the
type of disorder and response to the treatment (80). The location of the implant also plays
a major role in curing/reducing the condition of the disease (81-83). For example, in case
of Parkinson’s, stimulating the ventral intermediate nucleus of the thalamus (VIM) may
reduce only limbic tremor but has no effect on other manifestations of the disease;
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whereas stimulating the globus palidus (GPi) may reduce most of the major
manifestations of the Parkinson’s including the painful cramps, sensory symptoms, dopainduced dyskinesia and involuntary movements (84). In case of nociceptive pain,
stimulating the periaqueductal gray or periventricular gray may help in minimizing the
pain and for differentiation pain, stimulating the sensory thalamus may help (84).



Advantages of DBS
a. It is a highly reversible process; therefore there is no damage to the neuronal
tissue.
b. Programmable implants can control the dosage of stimulation depending on the
response to the treatment.
c. Stimulating specific regions of the brain can treat multiple neurological disorders.



Disadvantages of DBS
a. Extremely invasive technique.
b. A mechanical and functional failure demands replacement of implants through
neurosurgeries (usually once in 2-3 years).
c. Implantation of neurostimulators invasively is often followed by high risk of
infection. Extreme measures must be taken to protect the patient from developing
neural infections.
d. There is a small chance of permanent neurological complications that leads to
memory loss, change in thinking, personality disorders, loss of vision, and
paralysis.
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e. Cost of the surgery and maintenance of functional integrity of the implants could
be very expensive.

1.5. Non-invasive brain stimulation
Over the last decade the use of non-invasive brain stimulation methods for treating
multiple neurological (Parkinson’s, tics, epilepsy, tinnitus, stuttering, or dystonia) and
psychiatric (depression, drug craving, obsession, hallucination, catatonia, bipolar
disorders, mania, or trauma) disorders has rapidly increased. Even though these reported
(in literature) applications are poorly supported by the clinical data, the demand for the
non-invasive brain stimulation procedures is still enormous, benefiting the millions of
patients suffering from these dreadful disorders. Despite such a rapid growth and vast
applications of this procedure, most of the current techniques are either less effective or
require high intensity magnetic fields to stimulate the brain tissue. Hence, it is necessary
to develop a better technology to increase the efficiency and effectiveness of the
treatment. TMS, rTMS, and tDCS are the three most commonly used non-invasive brain
stimulation techniques to treat wide variety of neurological disorders. In TMS, local
magnetic pulses are generated using an insulated TMS coil (butterfly-shaped) placed over
the scalp by passing high amounts of electrical currents (>5KA) at the frequency of
1000Hz or greater. The local magnetic pulses generated by the TMS coil penetrate
through the skull and induce small eddy currents in the local conductive regions of the
brain tissue to depolarize the neurons. In rTMS, these currents are applied repetitively to
control the cortical excitability (increase/decrease) for longer periods (85). In tDCS, low
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amplitude direct currents (~2 mA) are generated constantly using a current generator that
is connected to a pair of saline-soaked sponge electrodes (20-35 cm2). These electrodes
are placed on the subject’s head as shown in Figure 5 to stimulate the brain tissue (86).
The direction of the flow of current through the sponge electrodes defines the type of the
tDCS, i.e. “cathodal” or “anodal”. The polarity of the tDCS plays a major role in the
modulation of cortical excitability. For example, cathodal tDCS will reduce the cortical
excitability, whereas anodal tDCS will increase it.

Figure 5: TMS and tDCS principles of non-invasive brain stimulation.

Recent pharmacology studies show that tDCS does not stimulate the neuronal firing; it
rather modulates the stimulated neurons (87). This property of tDCS separates it from
other stimulation techniques, such as TMS/rTMS. Note: during the stimulation process,
the subjects might feel an itching or tangling sensation on the scalp beneath the sponge
electrodes, which could be extremely painful (87). The advantages and disadvantages of
the TMS, rTMS, and tDCS technologies are explained in the following section.
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Advantages of TMS, rTMS, and tDCS techniques
a. They are cheap, safe, painless, and non-invasive.
b. No chance to develop post-surgical infections, as treatment is non-invasive
c. Zero recovery time. No restriction on patient’s activity before/after the
treatment procedure.
d. Highly reversible. No cognitive or systemic after effects (memory loss,
personality disorders, paralysis etc.,) due to non-invasive treatment.



Disadvantages of TMS, rTMS, and tDCS techniques
a.

High magnetic field used in TMS/rTMS leads to undesirable side effects.

b. The penetration depths and locality of focusing fields often limit the
effectiveness of the treatment.
c. Loud noises produced in TMS/rTMS often cause discomfort throughout
the treatment procedures. Moreover, patients undergoing tDCS also feel a
constant discomfort due to itching/tangling sensation beneath the sponge
electrodes.
d. Patients need to undergo the treatment procedure more often to make the
treatment effective.

In the next few chapters, we will introduce a new concept of using magneto-electric
particles (MENs) for non-invasive brain stimulation to address several disadvantages of
current non-invasive and invasive techniques to enable better neuronal stimulation
treatment procedures for eradicating neurological disorders.
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1.6. Brain electrical activity mapping
Brain imaging is either a direct or an indirect method of imaging the structural, functional
or the pharmaceutical information of the brain. Currently, brain imaging is performed by
several techniques, such as Magnetic resonance imaging (MRI), Positron emission
tomography (PET), Single photon emission computed tomography (SPECT), Computed
tomography (CT), Diffusion optical imaging (DOI), Functional-MRI (fMRI),
Magnetoencephalography (MEG), and Electroencephalography (EEG). Of all these
techniques, only MEG and EEG can provide the substantial information about the brain’s
electric fields. Electric fields in the brain (of the order femtovolts) are generated by the
net flow of ions through the nerve cell during the synaptic transmission (shown in Figure
6). These generated electric fields can be captured using either a MEG or an EEG
technique to track the neuronal firing (88, 89). Neurons are fired by all kinds of activities
performed by one’s brain, whether it is a heartbeat, locomotion or a basic conscious
thought. Tracking these brain dynamics through the electrical signal and correlating with
the associated activities is the ultimate dream of all the neurologists. Understanding this
neuronal activity plays a pivotal role in diagnostics and treatment of multiple
neurological disorders non-invasively (90, 91). In the following section, basic function of
the MEG/EEG along with their advantages, and disadvantages are discussed in detail.

1.6.1. Source of EEG/MEG signal
As previously stated, electric fields in the brain are generated by the net flow of ions
through the neurons during the synaptic transmission. The electric field by a single
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neuron cannot be detected at the scalp level due to the infinitesimal amplitude of the
signal, but can be detected if synaptic transmission takes in alpha rhythm (8-13 Hz) by
thousands of neurons (~50,0000). When the wave of these cumulative electric fields
reaches the scalp of the subject, the EEG electrodes mounted on the scalp can harvest, as
shown in Figure 6. In MEG, signal detection on the scalp level is from the orthogonal
magnetic fields produced by the flow of ions through the bundles of axons (called volume
conduction), which are oriented tangentially to the scalp surface as shown in Figure 6.
Spatial orientation of these axons plays a crucial role in determining the strength of the
EEG/MEG signal at the scalp surface. For example, if the axons are oriented oppositely,
the net magnitude of current generated due to the flow of ions will be zero and further,
will mitigate the process of volume conduction. Therefore, the signal in the EEG/MEG is
thought to be produced only by the pyramidal neurons in the cortex, as they are well
oriented and fired together (92). The signals from the deep tissue activities will fall off
(square of distance) before reaching the surface and would be impossible to detect at the
scalp level. Note: recording the signals at the scalp level over a period of time gives the
EEG/MEG signature of a particular activity in the cortex or sub-cortex but not from the
deep brain tissue (93).
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Figure 6: Signal in EEG/MEG. The synchronous firing of the neurons with the electrical currents and the
associated magnetic fields are illustrated in the image.



Advantages of brain mapping using EEG/MEG
1. Cheap, non-invasive, extremely sensitive to the cortical signals, and has
unlimited virtual time resolution.
2. Both the methods can provide information regarding the location and the
strength of the electrical activity in the brain (cortical).
3. Can be used, as a diagnostic tool in identifying the malfunctioning neurons
in diseased subjects (neurological). This information can be used later in
stimulating associated neurons by non-invasive brain stimulation methods
in the treatment process.
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Disadvantages of brain mapping using EEG/MEG
a. The primary disadvantage of both the techniques is requirement of
neuronal firing to be alpha rhythmic (for volume conduction) and also
demands the orientation of the neurons to be pyramidal.
b. Activities associated with the deep brain regions cannot be detected.
c. Very low spatial resolution.
d. Low signal-to-noise ratio.
e. Sophisticated data analysis.

1.7. Unique advantages of magneto-electric nanoparticles over the conventional
nanoparticles for biomedical applications
There are many different types of nanoparticle systems used in medicine for drug
delivery purposes alone. To mention a few, they rely on using thermally-responsive
polymers, optically (UV, Visible-Wavelength, and IR) or acoustically activated materials,
liposomes, electrochemical processes, and magnetic forces (94). In this case, the speed of
delivery is limited by the external field sources and not just by the blood circulation. For
instance, as it is related to the release across the blood-brain barrier (BBB), the magnetic
delivery provides a unique way to transfer drugs sufficiently fast to avoid their engulfing
by the reticuloendothelial system (RES) (95). However, all the existing delivery
technologies suffer from the lack of certainty of drug release from the carrier if and when
the nano-carrier reaches the target. Probably, the main stumbling block is the inability of
the current nanoparticle systems to remotely control the intrinsic phenomena that define
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the interaction of the nanoparticles with the surrounding cells and tissues. The
conventional approaches are extrinsic in their nature and often fail to adequately regulate
cellular phenomena, such as exocytosis of drug with intracellular vesicle, control of ionic
channels, using externally controlled signals (96). In other words, the fundamental
physics that underlies the nanoparticle system characteristics in the perspective of their
intrinsic interaction with the surrounding cells and tissues in the aforementioned
applications is barely exploited. Revealing and controlling the interaction of
nanoparticles at the nanoscale, whether it is electric field-, magnetic spin-, photon-, or
phonon-triggered, is vital for enabling perfect diagnostics and/or recovery/regeneration of
all the medical functions.

Our discovery of the unprecedented capabilities of MENs paves a way to fill this gap
through nanotechnology approaches. In this dissertation, we have shown that the intrinsic
quantum-mechanically defines coupling between electric dipoles and magnetic spins
within each nanoparticle, MENs could be used, as an energy-efficient and a dissipationfree field-controlled nano-vehicles for targeted delivery and on-demand release of antiCancer and anti-HIV drugs as well as nano-stimulators for non-invasive treatment of
patients with central nervous system (CNS) disorders, such as Parkinson’s Disease,
Alzheimer’s Disease, and other dementia (97). Further, this intrinsic coupling between
electric and magnetic fields within MENs provides molecular composition specificity that
can enable an entirely new dimension even to the conventional diagnostic methods, such
as MRI and PET-CT. In addition, the specificity allows assigning unique “passport”
features to small groups of nanoparticles thus pushing the real-time health monitoring
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capability to a new level. Finally, because the coupling between magnetic and electric
fields is achieved at the intrinsic level, ideally the described field-controlled PNM
functions (delivery, drug release, CNS stimulation, diagnostics) can be accomplished
with desirable (~100%) efficacy and without any destructive heat dissipation (with no
need to use high-power electronics as with the conventional NPs).

This dissertation presents the detailed fabrication protocols and characterization
procedures for MENs that could be used for energy-efficient field-controlled targeted
drug delivery and on-demand release with no heat dissipation and unprecedented high
efficacy. As examples, we discuss HIV and Ovarian Cancer models (In chapter 2, 3, and
4). Moreover, we also presented the potential applications of MENs in restoring the
neuronal activity in the brain and to function, as contrasting agents (for MRI and MNI
modalities) to capture molecular information of the surrounding tissue/microenvironment
(In chapter 5 and 6).

28

2. Chapter 2: Magneto-electric Nanoparticles for Eradicating HIV from CNS
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2.1. Introduction
Although highly active anti-retroviral therapy (HAART) has resulted in remarkable
decline in the morbidity and mortality in AIDS patients, zero or inadequately low
delivery of anti-retroviral (ARV) drugs

across the blood-brain barrier (BBB) and into

the brain and other tissue organs results in virus persistence (98-100). Hence, the
elimination of HIV-1 reservoirs still remains a formidable task (101, 102). In recent
years, use of nanotechnology in medicine has shown exciting prospect for the
development of novel remotely controlled drug delivery systems (103, 104). Besides
magnetic nanoparticles (MNs) (105-107), other delivery systems rely on using thermally
responsive polymers, optically (UV, Visible-Wavelength, and IR) and acoustically
activated nanostructures, liposomes, electrochemical processes, and others. An extensive
review of these and other active triggering approaches was presented in the article by
Timko et al (94). The unique advantages of magnetically forced triggering place this
approach in a class of its own. In this case, the speed of delivery is determined by the
external magnetic field. For instance, as it is related to the delivery across the BBB
(108), this approach provides a way to deliver drugs sufficiently fast to avoid their
engulfing by the reticuloendothelial system (RES). Nucleotide reverse transcriptase
inhibitor (NRTI) 3'-azido-3'-deoxythymidine-5'-triphosphate (AZTTP) is among the most
challenging antiretroviral (ARV) drugs to deliver across the BBB (109). Previously we
have shown that MNs tagged with AZTTP transmigrated across the BBB by application
of an external magnetic field without affecting the integrity of the BBB and the
transmigrated AZTTP demonstrated significant inhibition of HIV-1 p24 antigen
production in an in-vitro infection model system compared to the free AZTTP (95).
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However, this MN-based delivery suffers from the lack of certainty of drug release from
the carrier if and when the nano-carrier reaches the target. The current presumptive
mechanisms of drug delivery depend on manually uncontrollable cellular phenomena,
such as exocytosis of drug containing intracellular vesicle, intracellular Ca2+
concentrations and pathology-specific responses (change in pH, temperature, etc.) (96).
As a result, to obtain a relatively small physiologic change and ensure the release of the
drug, the binding force between the nano-carrier and the drug must be maintained
relatively weak. Consequently, more than 99% of the drug/carriers are deposited in liver,
lungs and other lymphoid organs before they reach the target. Therefore, an approach for
finely controlled and enhanced release of AZTTP in sufficient therapeutic levels in in the
brain or in other target organs is still sought after, as it is critical for the complete
eradication of HIV.

We present a study to demonstrate that dissipation-free, energy-efficient and low-field
on-demand drug release can be achieved if the conventional MN carriers are replaced by
magneto-electric (ME) nanoparticles (MENs) (110). ME materials represent a relatively
recently introduced class of multi-functional nanostructures in which magnetic and
electric fields can be strongly coupled at body temperature (64). Similar to the MNs,
MENs can be designed to have adequately high magnetic moments and therefore, also
can be used for targeted delivery by applying remote direct-current (d.c.) magnetic fields.
However, due to their non-zero magneto-electricity, unlike the traditional MNs, MENs
offer an additional feature that can enable a new dissipation-free mechanism to force a
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high-efficacy externally controlled drug release process at the sub-cellular level using
remote low-energy d.c. and/or alternating-current (a.c.) magnetic fields.

An exaggerated illustration in Figure 7 explains the concept of the field-triggered ondemand drug release from MENs. To simplify the description, we use an example with a
remote magnetic field in one specific direction, e.g. along X-axis, with respect to the
MEN-drug nano-complex. The original (zero-field) ionic bond, with charge Qionic of the
nanoparticle, is schematically shown in Figure 1a. AZTTP molecules (typically interconnected in chains) surround each MEN in a symmetric fashion. As shown in Figure 1b,
as a non-zero magnetic field is applied, a non-zero electric dipole moment is formed in
the nanoparticle due to the non-zero ME effect. For simplicity assuming an isotropic
model, the triggered dipole moment ΔP = αH, where α is the 1st order ME coefficient
and H is the magnetic field. The amplitude of the dipole charge surface density on each
side of the nanoparticle along the field would be of the order of σME ~ ±αH, where
“positive” and “negative” signs are applied to the opposite sides of the dipole,
respectively. The dipole moment breaks the original symmetry of the charge in the MEN
shell. Consequently, as the magnitude of the magnetic field is further increased above the
threshold value at which the dipole charge density on the “negative” side becomes
comparable to the positive ionic charge density in the shell, σME ~ Qionic/πd2, i.e. Hth ~
Qionic/πd2α, where d is the diameter of the MEN, the bond in this direction along the X
axis will be broken while the opposite bond will be further strengthened, as illustrated in
Figure 1c. By symmetry, to break the bond in the opposite direction, the field sequence
should be repeated in the reverse direction, as illustrated in figures 1D-E. This simplified
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scenario doesn’t take into account the randomness of the orientations of the
nanoformulations. Ideally, applying an AC magnetic field that equivalently sweeps all
bond orientations will create a more uniform and efficient bond-breaking process over the
surface of the nanoformulation and thus enhance the drug release efficacy. In the next
generation of the technology, this goal can be achieved by using a spatially rotating field,
which in turn can be accomplished, for example, by using an array of coils that generate
AC fields with non-zero phase shifts with respect to each other.

Figure 7: Illustration of the underlying physics of the a.c.-field-triggered release. A simplified (one-directional)
illustration of the concept of on-demand drug (AZTTP) release by MENs stimulated by a uniform a.c. magnetic
field in X-direction: (a) At zero field, only the ionic charge is present in the MEN shell; (b) An additional dipole
moment (proportional to the magnetic field) breaks the original symmetry of the charge distribution in the shell;
(c) As the field is increased above the threshold value (σ
σ ionic ~ σ ME), the bond on one side is broken. (d) and (e)
The field is reversed to break the bond on the opposite side of the nanoparticle. The red arrows show the electric
dipole due to the ME effect. In practice, due to the random configurations of nanoformulations with respect to
the field, the effect is present along every central bond orientation.

In this study, we verified the hypothesis by demonstrating the on-demand release of
AZTTP from 30-nm CoFe2O4@BaTiO3 MENs by applying low a.c. and d.c. magnetic
fields. We showed that a 44-Oe a.c. field at 1000 Hz was sufficient to trigger over 89%
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release. Further, to support the dissipation-free release model, we could use a 66-Oe d.c.
field to trigger a comparable release level.

2.2. Experimental methods
2.2.1. Preparation of CoFe2O4-BaTiO3 coreshell MENs
CoFe2O4 nanoparticles were prepared by hydrothermal method. In this method, 15ml of
aqueous mixture of 0.058g of Co(NO3)2.6H20, 0.16g of Fe(NO3)3.9H20 and 0.2g of
polyvinylpyrrolidone is dissolved in 5ml of aqueous 0.9g of sodium borohydride at 120C
for 12 hours. Next, precursor solution of BaTiO3 was prepared by mixing 30ml of
aqueous 0.029g of BaCO3 and 0.1g of citric acid with 30ml of ethonalic solution of
0.048ml titanium isopropoxide and 1g of citric acid. CoFe2O4@BaTiO3 coreshell MENs
are prepared by dispersing 0.1g of CoFe2O4 nanoparticles in the precursor solution. The
mixture was sonicated for 2 hours. Well-dispersed mixture was dried at 60°C for
overnight while stirring continuously. Later the mixture was subjected to calcination at
780°C for 5 hours. By reducing the cooling rate (controlled by furnace CMF 1100) from
above 52 to below 14 C/min, the average diameter of MENs could be controlled from
below 25 nm to over 100 nm, respectively, with an adequate size distribution of less than
30%. The particle size distribution was measured by a Zetasizer Nano series via the
standard dynamic light scattering (DLS) approach. For the 25-nm process (14 C/min
cooling rate), the average size distribution ranged from approximately 19 to 31 nm.
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2.2.2. Conjugating AZTTP with MENs (AZTTP-MEN Nanoformulations)
10µl of AZTTP drug (10mM, concentration) was added to the solution of 190µl of TE
buffer and 50µl of CoFe2O4-BaTiO3 coreshell MENs (5mg/ml). Then, the solution was
incubated for 2hrs and 3 hrs. After the incubation, the solution was subjected to the
magnetic field in-order to precipitate the MENs (conjugated with AZTTP). After the
supernatant was isolated, its absorption was measured at 267 nm using spectrophotometer
Agilent Cary 100.

2.2.3. Drug loading percentage
Drug loading percentage = (Absorbance of total amount of drug used – Absorbance of
drug used in supernatant after incubating the drug and the MEN for a specific incubation
time) x 100%:
After 2hr incubation, the percentage of the drug in the supernatant was ~89%, which
corresponded to approximately 11% (100-89) of the drug bound to the MENs. After 3hr
incubation, the percentage of the drug in the supernatant was ~76%, which corresponded
to approximately 24% (100-76) of the drug bound to the MENs.

Drug release percentage: drug release percentage =(absorbance of supernatant after
magnetic field treatment)/(absorbance of supernatant after incubating the particles with
drug) ×100%. The absorbance signal was measured at the maximum wavelength of 267
nm.
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2.2.4. Magnetic Field Treatment
To eliminate any potential residual unbounded drug, after isolating the supernatant, the
precipitate of the MENs conjugated with the drug was washed once with the TE buffer.
Then, the drug-conjugated particles (AZTTP-MEN nanoformulations) were re-dispersed
in 190µl of the TE buffer, and subjected to a magnetic field of varying field strength and
frequency (shown in Figure 8). Finally, the solution was precipitated to pipette out the
supernatant for further absorption measurements.

Figure 8: Magnetic fields treatment setup. Drug loaded MENs are treated in the uniform magnetic fields using a
pair of Helmholtz coils.
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2.2.5. Surface Charge of MENs and AZTTP Molecules
Because of the triphosphate functional groups, in the chemical (covalent and/or ionic)
bond between the MENs and the AZTTP molecular cluster chains, the CoFe2O4-BaTiO3
MENs and the AZTTP chains were positively and negatively charged, respectively.

2.2.6. Mass spectrometry analysis of AZTTP molecules, AZTTP bound to MEN
before and after the a.c.-triggered release.
After the a.c.-triggered release by MENs, we conducted a mass spectrometry analysis.
The analysis included a full scan qualitative identification of the target analyte, a
chromatographic separation and an assessment of the presence of the drug in the
composite material (AZTTP-MEN nanoformulations) using multiple reaction monitoring
(MRM) for appropriate transitions. Different mixes were contained in Eppendorf vials.
Using a 100-µL micropipette, 100 µL of each vial was transferred to a new disposable
polypropylene 96-well plate (Part # 5042-1386). The vials’ contents were subjected to a
flow injection analysis (FIA) using electrospray ionization with Jet Stream Technology in
both positive and negative mode to assess the presence of the AZTTP drug. The
measurements were conducted with mass spectrometer Agilent LC/MS Triple quadruple
G6460 LC-QQQ. The ionization conditions are presented in Table 2.

Figure 9

shows the

number of counts versus the mass-to-charge ratio for the three key stages of the release
process, (top) standard AZTTP, (middle) AZTTP bound to MENs, and (bottom) AZTTP
and MEN after the a.c.-triggered release of the drug load, respectively. The molecular
weight of the AZTTP molecule is approximately 507.
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Table 2: Mass spectroscopy instrumental parameters used for LC/MSD analyses (general screening method).

Source Parameter
Drying Gas Temp
Gas Flow
Nebulizer
Sheath gas heater
Sheath Gas Flow (l/min)
Nozzle Voltage
Capillary Voltage (Vcap)
Scan Parameters
Mass Range
Scan time
Fragmentor voltage
Cell Acelerator voltage
Polarity

Value
325 °C
10 psi
30 psi
375 °C
11
0V
3500 V
50-1000
350 ms
135 V
4V
Negative

Figure 9: Mass spectrometry analysis: the number of counts versus the mass-to-charge ratio for (top) the free
AZTTP, (middle) AZTTP and MENs in the bound state, (bottom) AZTTP and MEN after the a.c. release.
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2.2.7. Preparation of samples for AFM and FTIR imaging
10µl of AZTTP drug (10mM, concentration) was added to the solution of 190µl of the TE
buffer and 50µl of CoFe2O4-BaTiO3 coreshell MENs (5mg/ml). Then, the solution was
incubated for 3 hrs. After the incubation, one drop of solution was air dried on to a precleaned Si-wafer. Once dried AFM imaging (topography and phase contrast) were
performed using Nanoscope IIIa Multimode:
--For AZTTP: the above solution without MENs.
--For MENs: the above solution without AZTTP.
Note: for FTIR measurements, the sample preparation procedures were similar to the one
used for AFM.

2.2.8. In-vitro BBB Model
In-vitro BBB model was prepared according to the procedure described elsewhere (111).
The BBB model consisted of two compartments (upper and lower), which were separated
by the polyethylene terephthalate (PET) membrane of a 3.0 µm pore size (Becton
Dickinson Labware, NJ. USA). In a 24-well cell culture inserts, 2 × 105 human brain
microvascular endothelial cells (HBMEC) were grown to confluence on the upper-side of
the insert and the same amount of human astrocytes were grown on the underside. BBB
cell culture was incubated for 4 days in-order to reach incubation confluence at 37°C and
5% CO2. Transendothelial electrical resistance (TEER) was used to measure the
intactness of the BBB. The average TEER value for individual BBB was about 150 to
200 ohms/cm2, which is consistent with formation of BBB
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2.2.9. p24 Assay to confirm the integrity of AZTTP drug
Normal peripheral blood mononuclear cells (PBMCs) (10x106 cells) were infected with
native HIV-1Ba-L (NIH AIDS Research and Reference Reagent Program catalog no. 510)
at a concentration of 2ng/ml cells for 2 hours, washed with phosphate-buffered saline
(PBS) (GIBCO-BRL, Grand Island, NY) and returned to culture with and without fresh
(new) or MEN-released AZTTP at equimolar concentrations (200 nM). The culture
supernatants were quantitated for p24 antigen using a p24 ELISA kit (ZeptoMetrix,
Buffalo, NY) on the fifth day of infection. While the control sample showed the p24
concentration of approximately 33050 pg/ml, the use of fresh and MENs-released
AZTTP drugs resulted in the concentration values of approximately 1300 and 1800
pg/ml, respectively (Figure 10). Therefore, considering the standard deviation of
approximately 300 pg/ml, the two drug forms demonstrated equal p24 inhibition efficacy.

Figure 10: P24 study to prove that the on-demand release does not affect the inhibition efficacy of the AZZTP
drug. The P24 concentration is in pg/ml (units).
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2.2.10. In-vitro cytotoxicity assay
To understand the in-vitro cytotoxicity of MENs (CoFe2O4@BaTiO3), we performed
XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]2H-tetrazolium inner salt) assay according to the manufacturer’s protocol (ATCC). XTT
is a quantitative colorimetric assay, which is based on the formation of an orange colored
formazan dye by viable cells from the cleavage of XTT tetrazolium salts. The assay was
performed on human astrocyte (HA) cells for neuronal cytotoxicity and on peripheral
blood mononuclear cells (PBMc) for peripheral cytotoxicity. In this assay, desired cells
were seeded in a 96-well cell culture plate at a 1×105 cells/well concentration and
incubated for 48 hours. Note: performing a pre-assay optimization protocol standardized
the cell concentration and incubation time (show in Figure 11). Following the incubation,
the cell culture medium was replaced by a medium containing MENs at a differential
concentration of 0-to-50µg/ml. The cells were incubated in the MEN solution for 24
hours. Once, the incubation period was completed the cells were washed with PBS buffer
and later supplemented with a fresh medium. Cell viability test was performed by XTT
test kit, as supplied by (ATCC) for 6 hours. The experiments that were performed in
triplicate indicated no significant toxicity at a concentration of less than 50 µg/ml (shown
in Table 3).

41

Figure 11: XTT assay optimization assay results for human astrocyte cells for different treatment times (2, 4,
and 6 hrs.).

Table 3: Cell viability test (XTT) to illustrate non-toxicity of MENs at different concentrations.

MEN Concentration
(µg/ml)
0
10
20
30
40
50

Cell viability percentage for different cell types (%)
HA

PBMCs

100 ± 0.3
100.1 ± 1.2
99.8 ± 3.6
98.3 ± 2.1
96.1 ± 3.5
95.9 ± 2.6

100 ± 2.7
99.91 ±1.1
99.94 ± 0.2
99.76 ± 2.7
98.78 ± 1.5
98.38 ± 0.2
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2.3. Results
We used atomic force microscopy (AFM) in conjunction with UV-spectrophotometry,
Fourier Transform Infra-Red (FTIR) analysis, and mass spectroscopy to directly trace the
kinetics of the drug release process at different stages of the release under the influence
of remote d.c. and a.c. magnetic fields. The three key stages included (i) the initial state
with separate MEN carriers and AZTTP molecules, (ii) the loaded state in which MENdrug nano-formulations are formed, and (iii) the final state after the a.c.-field-forced
separation of AZTTP and MENs, i.e. after the on-demand drug release. In-vitro
experiments on HIV-infected human cells were conducted to demonstrate the structural
and functional integrity of AZTTP after this physical release process. Below we present
the key results of this experimental study. The experiments are described in more detail.

2.3.1. Transmission electron microscopy study of MENs
In the experiments described below, for the role of MENs we used nanoparticles made of
the popular core-shell composition CoFe2O4@BaTiO3, in which the relatively high
moment CoFe2O4 core was used to enhance the magnetic moment (112). In general,
nanoparticles as small as 5-nm in diameter can be fabricated with physical methods, such
as ion beam proximity lithography or imprint lithography (113).

In this study,

considering the novelty of the approach, we focused on the main discovery of using
MENs for on-demand drug release rather than on the development of scaling approaches.
The default measurements were conducted with 30-nm MENs. A typical transmission
electron microscopy (TEM) image of the fabricated MENs, with clearly visible core-shell
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structures, is shown in Figure 12A. The composition of the MENs was confirmed through
energy-dispersive spectroscopy (EDS), as shown in Figure 12B. The ME coefficient for
the nanoparticles was measured via point I-V methods in the presence of a field to be the
order of 100 V cm-1 Oe-1 using an approach described in our previous publication (114).

Figure 12: Transmission electron microscopy analysis of MENs. (a) A transmission electron microscopy (TEM)
image of MENs. The core-shell structure of MEN is highlighted. The scale bar is 100 nm. (b) An energydispersive spectroscopy (EDS) analysis of MENs.

2.3.2. Spectrophotometry study of the release
The goal of the first experiment was to measure the amount of the drug (AZTTP) at
different stages of the release process using the conventional approach of
spectrophotometry by measuring the UV-light absorption at the 267-nm maximum of the
drug’s absorption spectrum. We could bind approximately 24% of the drug to the
nanoparticles by incubating AZTTP with the MENs in the Tris-EDTA (TE) buffer (pH
7.4) for 3 hours. The amount of the bound drug was determined by estimating the
concentration of AZTTP in the unbound fraction (supernatant) of the incubation mixture
by spectrophotometry. To apply remote d.c. and a.c. magnetic fields, we used a low-
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energy low-field Helmholtz pair connected to a function generator. The chart in figure 3
summarizes the key results of this experiment, in which we measured the amount of the
unbound drug depending on the external field strength and frequency. It can be seen that
application of a 44-Oe field at 1000 Hz results in 89.3% of the drug being released, while
application of a d.c. field of the same amplitude releases only 16.4% of the drug. The data
also confirms that with higher frequency, a lower magnetic field is needed to break the
bonds because oscillation of the bonds caused by a higher frequency field facilitates the
breaking of the bonds. However, when a strong enough d.c. field (>~65 Oe) is applied,
the bond-breaking side of the drug chain can gain enough momentum, causing the chain
to break free from the MEN shell even at zero frequency. To fully exploit the potential of
the new controlled drug release nanotechnology, it is important to conduct a more
detailed pharmacokinetics study.

Figure 13: Field strength and frequency dependence of the drug release. Chart showing the release efficacy of
AZTTP drug bound to MENs by a remote magnetic field at different amplitudes and frequencies.
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2.3.3. Pharmacokinetics study
In this experiment, MENs loaded with AZTTP drug were exposed to an external
magnetic field at different strengths (12 Oe, 44 Oe and 66 Oe) and frequencies (0 Hz, 100
Hz, 1000 Hz) at different treatment durations (1, 5, 10, 60, and 120 minutes) in-order to
understand the release kinetics. Results are summarized in the 3-D chart in Figure 14.
The quantitative values are also presented in Table 4. For every field-frequency
combination set we used a fresh solution with AZTTP-loaded MENs.

Figure 14: Pharmacokinetics study. Pharmacokinetics Study: 3-D Chart representation of the drug release
percentage at various combinations of the field strength (12, 44, and 66 Oe), the frequency (0, 100, and 1000 Hz),
and the treatment duration (1, 5, 10, 60, and 120 min).
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Table 4: Drug release percentage at various combinations of field strength, frequency, and treatment duration

Field

12 Oe

44 Oe

66 Oe

Frequency

Drug Release Percentage for Different Field Treatment
Durations (minutes)
1

5

10

60

120

0 Hz

1.31%

1.50%

1.52%

1.87%

1.81%

100 Hz

6.40%

10.14%

32.20%

36.80%

37.89%

1000 Hz

7.81%

15.73%

96.20%

98.01%

98.7%

0 Hz

5.01%

4.90%

5.10%

5.32%

5.41%

100 Hz

23.30%

39.58%

85.60%

95.66%

98.00%

1000 Hz

47.77%

85.33%

99.01%

99.15%

99.31%

0 Hz

33.30%

33.90%

40.23%

41.60%

44.77%

100 Hz

98.05%

99.21%

98.71%

99.21%

99.27%

1000 Hz

98.58%

97.65%

98.37%

99.31%

99.11%

2.3.4. Fourier-transform infra-red analysis
The concept of the drug release by a remote magnetic field was confirmed also through
Fourier Transform Infra-Red (FTIR) analysis, as shown for the three key stages of the
process kinetics in Figure 15: (top) free MENs and AZTTP before loading, (middle)
loaded state: MEN-AZTTP nanoformulations, and (bottom) MENs after the AZTTP
release by a remote 44-Oe field at a 100-Hz frequency. Compared to the initial and final
unbound states, the loaded state showed almost 30% weaker absorbance in general and a
transformed spectrum in the wavenumber region from 1750 to 1250 cm-1.
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Figure 15: FTIR measurements. FTIR measurements for MEN-AZTTP system at three different stages: (i)
(top) MENs only, (ii) AZTTP-loaded MENs, and (iii) MENs after the release by the a.c.-field treatment.

2.3.5. Atomic force microscopy study of the release kinetics
To observe the release process at the molecular level, we conducted the following AFM
measurements. Figure 16 shows a sequence of AFM images that reflect the following
four stages of the release process: free (a) MEN and (b) AZTTP chains, (c) loaded MENAZTTP nanoformulations, and (d) MENs and (e) AZTTP after the release by a 44-Oe a.c.
field at 1000 Hz. To obtain images c and d, the unloaded drug was washed away with the
supernatant. One can observe that the MENs and AZTTP chains before the loading step
and after the release process look similar.
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Figure 16: Atomic force microscopy study of the drug release kinetics. AFM images at different stages of the
release process: (a) MENs and (b) AZTTP chains before the loading (binding) step, (c) AZTTP-MEN
nanoformulations after the loading process, (d) MENs and (e) AZTTP after the drug release by a 44-Oe a.c. field
at 1000 Hz. The scale bar is 100 nm.

2.3.6. Field-controlled delivery and drug release by MENs loaded with AZTTP
across BBB in in-vitro model.
Translocation experiments were performed on day 5 of BBB cell culture. In-order to
achieve the translocation of AZTTP across the BBB, AZTTP were loaded on MENs and
subjected to an external magnetic field of 40 Oe (to avoid any unwanted drug release at
higher fields) for 3 hours and a gradient of approximately 22 Oe/cm (to pull the
nanoparticles across the BBB) for 6 hours of the incubation period. To apply a field
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normal to the BBB, the field coils were placed below the cell culture wells carrying the
BBB model. Once the incubation was completed, the medium in the bottom chamber was
isolated and subjected to the a.c. magnetic field (66 Oe at 100 Hz field for 5 minutes) to
increase the release percentage. After the field treatment, the MENs were isolated via a
magnetic separation technique. Once separated, the supernatant was measured for the
drug concentration via spectrophotometry. The results indicated that approximately 40 %
of the drug was translocated across the BBB, as a result of the process. These results are
summarized in Figure 17. To further confirm the structural and functional integrity of the
drug after the a.c. release process, we conducted: (i) a mass spectrometry analysis of the
drug before and after the release (Figure 9), (ii) an in-vitro experiment to study the p24
inhibition efficacy of the drug before and after the release (Figure 10). Finally, to
understand the cytotoxicity of MENs (CoFe2O4@BaTiO3), we performed an XTT assay
on human astrocyte (HA) cells for neural cytotoxicity and on human peripheral blood
mononuclear cells (PBMc) for peripheral cytotoxicity.

The results indicated no

significant toxicity at a concentration of less than 50 µg/ml (Table 3).

Figure 17: AZTTP-MEN translocation of across BBB.
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2.4. Discussion
The spectrophotometry experimental results (Figure 13) indicate the threshold value,
necessary for the field to start the release of the AZTTP drugs by the MENs, to be of the
order of 10 Oe, even though only 10% of the drug was released at such a low field value.
Using the simplified expression we derived above for the release threshold field (Hth ~
Qionic/πd2α) and assuming the nanoparticle diameter d = 30nm and the ME coefficient α
= 100 V cm-1 Oe-1, we can evaluate the value for the effective charge, Qionic (responsible
for the ionic/covalent bond between the MEN and AZTTP cluster), to be approximately
10-17 C. The estimate seems reasonable and indicates that approximately a few hundred
electrons are involved in the bond formation. Further, in agreement with the original
hypothesis, the experiment also proves that the a.c. field provides a substantially more
enhanced release compared to that of the d.c. field. Indeed, at 12-Oe field amplitude, d.c.
and a.c. (100 Hz) fields results in 1.9 and 10% released drug percentage, respectively. To
achieve almost full (89.3%) drug release, a field of 44 Oe at a frequency of 1000 Hz is
required. The effect of the a.c.-field control is significant in this case. For comparison,
with a field of 44 Oe at the frequency of 100 Hz, the released amount was 28.5% while
for the d.c. case at the same field amplitude was only 16.4%. The experiment indicates
that such nanoformulations can be directed to the targeted cells via a d.c. magnetic field
with a spatial gradient while the drug can be effectively released on demand via an
external a.c. magnetic field at 1000 Hz. Note that the highest applied field of 65 Oe
immediately saturated the system resulting in an almost full drug release even in the d.c.
case. According to our hypothesis, the magnetic-field-triggered large electric force that
gave enough momentum to break the bond can explain the latter. The results of the more
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detailed pharmacokinetics study (Figure 14) also indicate the presence of a certain
threshold field that needs to be applied to trigger the release. The threshold values at
different frequencies reach their saturation value in about 60 minutes of the incubation
process. Again, this threshold field exists even in the d.c. case (zero frequency) and can
be further reduced in the a.c. case by increasing the frequency of an a.c. field. To separate
the d.c. and a.c. functions for drug delivery and release, respectively, it is important to
maintain the amplitude of the field below the saturation value, e.g., at 44 Oe. This
separation of the d.c.- and a.c.-driven delivery and release functions, respectively, was
also confirmed in the in-vitro experiment with a human BBB cell culture (Figure 17). The
FTIR results are in agreement with spectrophotometry data (Figure 15). Supporting the
above release model, the initial state (before drug loading) and the final state (after the
release) FTIR spectra look similar while the altered intermediate state reflects the effect
of binding between MENs and AZTTP molecules. The AFM measurements (Figure 16)
directly illustrate the physical difference between MEN-AZTTP nanoformulations and
the free MENs before loading and after releasing the drugs. In agreement with the
described spectrophotometry and FTIR measurements, the AFM analysis also indicates
that the MENs return to their original unbound state after the drug release triggered by
a.c. magnetic field. In addition, AFM also proves the nanoscale nature of the approach,
with the potential to be applied at the sub-cellular level. The in-vitro experiment using
human PBMCs infected with HIV-1Ba-L proves the intact integrity of the drug after the
a.c.-triggered release (Figure 10).
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The fundamental difference between MNs and MENs is due to the presence in the latter
of the quantum-mechanically caused ME effect that enables intrinsic coupling between
the magnetic spin and the electric dipole. Consequently, energy-efficient and dissipationfree remote control of the intrinsic charge distribution in the MENs (and consequently,
control of the bonding force between the MENs and the drug) can be enabled via
application of an external magnetic field. Because of the intrinsic ME effect, even if the
drug is strongly bonded to the MEN carriers (as required for high-efficacy delivery), it
can be fully released at the target location via application of a local magnetic field with a
strength above a certain threshold defined by the ME effect. For comparison, the drug
release process using the conventional MNs is not controlled at the same fundamental
level but instead, is based on an irreversible energy dissipation process caused by an
external a.c. magnetic field. In one MN implementation, superparamagnetic nanoparticles
and drug molecules are incorporated into temperature-sensitive synthetic polymers or
other biomaterials that release the drug, as the nanoparticles are heated under the field
exposure (115). In other implementations, superparamagnetic nanoparticles can be coated
with intermediate linkers (tailored to specific load molecules), embedded in a ferro-gel,
or directly connected to the load molecules (116). In either of these conventional cases,
the release mechanism with MNs is based on extrinsic phenomena, e.g. mechanical
deformation and/or heat dissipation that affects the release kinetics, that are triggered by a
relatively high frequency a.c. field (in the range of hundreds of kilohertz or above) and
consume a substantial amount of power (in the kilowatt range). On the contrary, the
MEN-triggered release process is achieved at the intrinsic level and does not require any
intermediate materials. It is dissipation free and extremely energy efficient. The release
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with MENs can be triggered by an a.c. magnetic field at a relatively low frequency
(below 100 Hz) and even at a d.c. field provided the field strength is above a certain
threshold value, as described below in more detail, with power consumption in the subwatt range.

One can argue that MENs may also experience the potential problem of having a
relatively large fraction of the nanoparticles (together or without the drug) trapped in the
reticuloendothelial system. One solution to this problem is to apply a “zig-zag” shaped
time-varying field profile to move the nanoparticles through the system. Then, besides
the force along the main delivery path, there is a significant “jolting” force normal to this
direction. This “jolting” force ensures that the nanoparticles don’t become trapped in the
fibers of the reticular connective tissue. However, application of the strongly inertial
“zig-zag” force to the conventional MNs can also result in a significant loss of the drug.
On the contrary, with MENs, the physical bond between the drug and the nanoparticle
can be engineered to be adequately strong to avoid any loss until a command to release is
given via an external field.
2.5. Conclusion
As a final conclusion, we would like to emphasize that although MENs indeed have a
unique advantage of serving in both roles, (i) as regular MNs for drug delivery (via
application of a d.c. remote field with a spatial gradient), and (ii) as drug release
nanoscale sites, their capability of an on-demand drug release by application of a low
remote magnetic field in an extremely low frequency range is unprecedented and
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therefore is a merit of its own (even without exploiting the drug delivery feature). In
general, this physically controlled release method could be complementary to any other
drug delivery and tagging mechanism, whether it is physical or chemical. Although
AZTTP is used in the experiment, the ability of on-demand drug release by a MEN nanocarrier discovered in this study is also relevant to the treatment of other diseases, such as
many CNS diseases, cancer and others where deep-tissue high-efficacy drug delivery at
the sub-cellular level is key.

Note: How to cite this chapter: The content of this chapter is published in my Nature
Communications article, hence please use this as a reference: Nair, Madhavan, Rakesh
Guduru, Ping Liang, Jeongmin Hong, Vidya Sagar, and Sakhrat Khizroev. "Externally
controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as
carriers." Nature communications 4 (2013): 1707.
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3. Chapter 3: Magneto-electric Nanoparticles to Enable Field Controlled Highspecificity Drug Delivery to Eradicate Ovarian Cancer Cells
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3.1. Introduction
The development of a technology that is capable of high-specificity targeted delivery of
antineoplastic drugs would be a significant breakthrough in cancer in general and ovarian
cancer in particular. Although the circulatory system can deliver a drug to every cell in
the body, delivering the drug specifically inside the tumor cell past its membrane without
affecting the healthy cells remains a challenge (117-119). In ovarian cancer,
intraperitoneal (IP) delivery through a surgically implanted catheter has shown improved
survival rates. However, catheter complications and toxicity have precluded widespread
adoption of this invasive means of delivery (120). Current research attempts to go around
these limiting factors by using nanoscale systems. In this case, the drug is administered
non-invasively through intravenous (IV) injection (103, 104, 121). Often, as immunological
reagents, monoclonal antibodies are used to recognize the tumor-specific biomarker while the
nanoscale control further improves the specificity and targeted drug delivery capability in
general. Nonetheless, in spite of the tremendous progress in this field during the last

decades, the capability of targeted delivery with adequately high specificity (to tumor
cells) remains an important roadblock to finding a cure for cancer. In this paper, we
present a study in which we address this challenge through a new physical concept. It
exploits (i) the difference in the electric properties of the membrane between the tumor
and healthy cells and (ii) the ability of the recently discovered body-temperature
magnetoelectric nanoparticles (MENs) to function, as nano-converters of remotely
supplied magnetic field energy into the MENs’ intrinsic electric field energy (110, 122,
123). Like the conventional magnetic nanoparticles (MNs), MENs have a non-zero
magnetic moment and therefore can be controlled remotely via application of an external
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magnetic field. However, unlike MNs, MENs offer a new far-reaching function, which is
a dissipation-free and energy-efficient control of the intrinsic electric fields within the
nanoparticles by an external magnetic field. This unprecedented capability is a result of
the strong magneto-electric (ME) coupling in this new class of nanostructures even at
body temperature. Like the conventional magnetic nanoparticles (MNs), MENs have a
non-zero magnetic moment and therefore can be controlled remotely via application of an
external magnetic field. However, unlike MNs, MENs offer a new far-reaching function,
which is a dissipation-free and energy-efficient control of the intrinsic electric fields
within the nanoparticles by an external magnetic field. This unprecedented capability is a
result of the strong magneto-electric (ME) coupling in this new class of nanostructures
even at body temperature (64, 124-126). As a result, MENs introduced in a biological
microenvironment act, as localized magnetic-to-electric-field nano-converters that allow
remote control and generation of the electric signals that underlie the intrinsic molecular
interactions. Recently, we exploited this capability: (i) to achieve remotely-controlled
brain stimulation in patients with Parkinson’s Disease by applying low-energy a.c.
magnetic fields to control the a.c. electric signals in the central nervous system (CNS)
using intravenously injected MENs and (ii) to deliver and release on-demand (via an
external field) anti-retroviral (ARV) drug AZTTP for treatment of HIV-1 reservoirs
across the blood brain-barrier (BBB) (1, 97). In this study, we exploit this capability to
achieve the field-controlled specificity of the drug-loaded MENs, as required to
significantly improve the state of chemotherapy.
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Figure 18: Hypothesis illustration: MENs as field-controlled nano-electroporation sites to let the drug through
the cancer cell membranes. An artist’s view that illustrates how the electric medium in the cell membrane in the
vicinity of MENs can effectively act as a field-controlled array of nanoscale localized valves for the drug-loaded
MENs to enter the cell. The “valves” are open as the remote magnetic field is above the first critical value, Hth,
specific to the cell. This value for the tumor cell is at least a factor of two lower than that for the healthy cell. As
the field is further increased above the second critical field, Hr, the release is initiated.

With regards to achieving the required specificity to the tumor cells, the MEN’s new
capability to control the local electric fields remotely opens an exciting and previously
unexplored path to exploit the intrinsic electric properties of the cell membrane. Due to
the presence of ion channels and other electric-field driven properties, the cell membrane
is an electrically polarizable medium. As a result, its properties can be significantly
affected by an electric field. For example, electroporation is one such well-known
characteristic that reflects the effect of the change in the membrane’s porosity in the
response to a large electric field (127). The electroporation has been widely studied, as a
means to trigger drug delivery into the tumor cells. Through macroscale studies (with
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centimeter sizes) it is known that the electric field of higher than 1000 V/cm creates
sufficiently large pores for the drug to penetrate through the membrane. Our approach
was to use MENs to generate such high large electric fields (by remotely exposing them
to relatively small magnetic fields) only in a very small (nanoscale) region in the vicinity
of individual MENs. By the law of scaling, when exposed to magnetic fields, MENs
loaded with the drug and the biomarker-specific antibodies (for delivery to the tumor
cells) can generate localized (at nanoscale) fields large enough to open up the membrane
pores in their proximity only and thus let the drug inside the tumor cells. Because this
process is extremely energy efficient, all the used energy goes to fulfill the main
operation (of opening up the local pores, i.e. nanoscale electroporation) and consequently
it doesn’t result in any significant and potentially damaging energy dissipation, e.g., in
terms of heat. This strongly localized near-field electric effect (with the localization
defined by the size of the nanoparticles) is triggered by an external magnetic field
because of the strong ME coupling within each nanoparticle. Due to the localized nanoelectroporation effect, this interaction between the MENs and the electric system of the
membrane can effectively serve, as a field-controlled valve to let the drug-loaded
nanoparticles enter specifically the tumor cells only. An artist’s view of the main
hypothesis is presented in Figure 18. In this case, the origin of the specificity to the tumor
cells would be two-fold. First, the biomarker-specific antibodies steer the drug-loaded
MENs (to which they also are attached) to the tumor cell membrane. Second, even higher
specificity is achieved due to the fact that the tumor and healthy cells have different
values of the threshold field, Hth, for the valve to “open up”. Indeed, it is well-known
that the electric properties differ significantly between the healthy and tumor cells of the
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same type (128).

For instance, the rat hepatocytes and hepatoma cells have mean

membrane potentials of approximately -40 and -20 mV, respectively. In general, the
tumor cells have substantially lower values of the potential compared to that of the
healthy cells. Consequently, the cancer cells must also have a significantly lower value of
the threshold field to “open up” the membrane “valve” for the drug-loaded MENs to enter
the cell. Considering the typical value for the ME coefficient α = 100 V cm-1 Oe-1,
according to the simple isotropic expression for the ME effect, ΔP = αH, where P and H
stand for the induced electric dipole field and the external magnetic field, respectively,
the electric field of the order of 1000 V/cm can be easily generated a few nanometers
away from the MEN merely by applying a weak magnetic field of 10 Oe. Because this
value is comparable to the field necessary for triggering the cell electroporation effect at
the nanoscale, each MEN in the vicinity of the cell acts, as the cell’s field-controlled
nano-electroporation site. After the drug-loaded MENs penetrate into the cell cytosol
through the “open” pores in the membrane, the drug can be released off the MENs by
further increasing the field above the second critical value, Hr, necessary for overcoming
the drug-MEN binding energy. We described the underlying physics of this fieldcontrolled drug release process in a recent article (1). This field strongly depends on the
binding force between the MEN and the drug and consequently can be tuned in a large
range through using different intermediate coating materials, field excitation frequencies
and treatment durations. In summary, according to our hypothesis, there are two critical
field values, Hth and Hr, which define the drug penetration threshold through the tumor
cell membrane and the following release of the drug into the cell cytosol, respectively.
To ensure adequately high efficacy of the uptake, we need Hr > Hth. To ensure the
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required specificity of the uptake to the cancer cells only, the external applied field, HA,
needs to be higher than the release field for the tumor cells, Hr_cancer, and lower than the
threshold field for the healthy cells, Hth_healthy. In summary, using MENs not only can
provide field-controlled delivery, but also can significantly improve the specificity to
tumor (compared to the specificity defined by the monoclonal antibodies alone). When
combined, monoclonal antibodies and MENs make a better delivery system. While the
monoclonal antibodies steer the loaded drugs towards the surface of the tumor cells, the
field-controlled MENs move the drugs across the cell membrane into the cytosol.

This new high-specificity nanotechnology can be applied to the treatment of cancer in
general. In the current study, to prove our hypothesis, we use Epithelial Ovarian Cancer
(EOC). EOC has been widely studied in the medical community (129). Cytoreductive
surgery followed by chemotherapy with mitotic inhibitor Paclitaxel (PTX) with platinum
is the gold standard in treating EOC.

In most cases, the drug administration is

intravenous (IV). Less commonly the administration is intraperitoneal (IP). As noted,
there are technical considerations and limitations to IP therapy, although it is more
effective than intravenous therapy. In either case, the specificity of the drug uptake is still
relatively low and, as a result EOC remains a highly lethal malignancy. Therefore, the
current study is relevant to this field. In addition, because of the high-specificity
capability, the new nanotechnology can be used for targeted treatment of both localized
and metastasized tumor cells.
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3.2. Experimental methods
3.2.1. Preparation of CoFe2O4-BaTiO3 Coreshell MENs
For preparation of coreshell MENs please refere to section 2.2.1.
3.2.2. Preparation of GMO- MENs
In-order to load the PTX drug onto the MENs’ surface; the nanoparticles were first
coated with GMO to adjust the release field at about 30 Oe, as required for this
application. To achieve this, 1 mg of GMO was added to 5 mg of MENs in 5 ml of the
PBS buffer. The mixture was then incubated for 12 hours while being slowly rotated in
order to achieve uniform coating.

Upon completion of the incubation process, the

nanoparticles were centrifuged at 20,000 rpm for 20 minutes at 10° C. The pellet was
washed in ethyl acetate:acetone (70:30) solution and re-centrifuged. The washing process
was repeated thrice to completely remove the excess unbound GMO. Finally, the
obtained pellet was lyophilized for 48 hours and stored for further use. The results of the
energy dispersion spectrometry (EDS) that depict the materials composition of GMOMENs are summarized in Figure 19.
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Figure 19: Energy dispersion spectroscopy of MENs. Energy dispersion spectroscopy (EDS) results depict the
composition of (a) MENs only and (b) GMO-coated MENs.

3.2.3. Preparation of HER-2 biomarker antibody conjugated GMO- MENs
HER-2 biomarker antibodies were covalently attached onto the GMO-MENs’ surface
according to the protocol described by Kocbek et al (130). In-order to covalently attach
the HER-2 antibodies, the nanoparticle surface was preliminarily functionalized. For this,
1mg of GMO-MENs were added to 500µl of the PBS buffer (pH 7.4). To this solution,
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25µl of N-(3-Dimethylaminopropyl)-N’-ethyl-carbodiimide hydrochloride (EDC) and
25µl of N-hydroxysuccinimide (NHS), at 1 mg/ml concentration in the PBS buffer (pH
7.4) were added. The solution was incubated for 4 hours at room temperature while
being stirred slowly. Then, the sample was centrifuged at 14,000 rpm for 10 minutes at
10° C and the pellet was washed three times with 1 ml of the PBS buffer (pH 7.4). To
bind HER-2 antibodies to the functionalized MENs, 10 µl of the antibodies (1 mg/ml)
was added to the pellet along with 300 µl of the PBS buffer (pH 7.4). The solution was
incubated for 2 hours while being rotated slowly and kept further at 4° C overnight. The
solution was centrifuged at 14,000 rpm for 10 minutes at 10° C. The pellet was washed
thrice with 1 ml of the PBS buffer (pH 7.4) to remove any excess antibody. The
supernatant was collected to determine the amount of the unconjugated HER-2 protein by
comparing to the standard plot. A standard calibration plot for HER-2 was obtained by
varying the concentration in the range of 1.25-10 µg/ml using Bio-Rad protein assay kit
(Braford method) through measuring the absorbance at 595 nm using spectrophotometer
Cary-100 (Figure 20). The percentage of the conjugated HER-2 was obtained using the
following expression: the percentage of HER-2 conjugated = (the total amount of HER-2
added – the amount of the unconjugated HER2 present in the supernatant) × 100. The
results indicated that over 70 % of the HER-2 antibodies were conjugated to the GMOMENs’ surface.
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Figure 20: Standard HER-2 antibody concentration calibration curve. Standard HER-2 Antibody plot was
obtained using Bio-Rad protein assay kit at 595 nm absorbance.

3.2.4. Preparation of drug loaded MENs
After 50 µg of PTX drug was added to the solution of 900µl of the modified PBS
(MPBS) buffer and 100 µl of the desired MEN combination (i.e. MENs, GMO-MENs,
and HER-2-GMO-MENs at a 5 mg/ml concentration), the solution was incubated for 3
hours while stirred slowly to obtain uniform binding. Then, the solution was centrifuged
at 14,000 rpm for 10 minutes at 10° C to remove any unbounded drug. The supernatant
was isolated and absorbance was measured spectrophometrically at 230 nm using Cary100 UV-VIS spectrophotometer (131). The PTX loading percentage is shown in Figure
21. A standard calibration plot for PTX was obtained by varying the drug concentration
from 5 to 80 µg in 1 ml of the MPBS solution and the absorbance was measured at 230
nm. The absorption maxima and the standard linear calibration plot of PTX at different
drug concentration values are shown in Figure 22.
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Figure 21: PTX drug loading percentages. PTX drug loading percentage for MENs,
GMO-MENs and HER-2-GMO-MENs after 3 hrs. incubation (n=3).

Figure 22: PTX calibration plot. The absorption maxima and the standard linear calibration plot for PTX at
different drug concentration values determined spectrophotometrically.

3.2.5. Cell culture experiments
Cell culture experiments were performed using human ovarian carcinoma cell line
(SKOV-3) purchased from American Type Culture Collection (Manassas, VA) and were
cultured in McCoy’s 5A medium (Life Technologies, NY) supplemented with 10% fetal
bovine serum (Sigma-Alrich) and 1% penicillin-streptomycin (science-cell). Human
Ovarian Microvasicular endothelial cells (HOMEC) from ScienceCell (Carisbad, CA)
and were cultured in endothelial cell medium with endothelial cell growth supplement
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(1%), fetal bovine serum (5%), and penicillin-streptomycin (1%). All the cells were
cultured at 37° C cell incubator with a 5% CO2 and humidified atmosphere.

3.2.6. Fluorescence measurements and confocal imaging of drug uptake by
SKOV-3 cells for different drug-carrier combinations
Cellular drug uptake measurements and fluorescence imaging were performed using an
Oregon Green® 488 paclitaxel (also called Flutax-2). The experiments were performed in
dark. For the fluorescence measurements, the SKOV-3 cells were cultured in 24-well
plate at a density of 2 × 105 cell per well. After 24-hour incubation at 37° C, the cell
medium was replaced with 1 ml/well of the medium containing either one of the four
desired drug forms. The concentration of Flutax-2 was normalized to 0.75 µM (1.76
µg/ml) for all the combinations. The cell culture plate was returned to the incubator and
incubated for 10 hours. In addition, a set of controls containing no drug for all the
combinations was cultured under similar conditions. The cell culture plates containing the
Flutax-2-MNs and Flutax-2-GMO-MENs were kept under a 30-Oe field.

Upon

completion of the 10-hour incubation process, the cells were removed from incubator and
the cell culture medium was discarded. The cells were washed with ice-cold PBS buffer
thrice. Then, 1 ml of dimethyl sufloxide (DMSO) was added to each well and incubated
for 2 hours at 37° C. After two hours, a rubber policeman was used to ensure the
complete removal of the attached cells. The solution was centrifuged at 14,000 rpm for
10 minutes at 4° C to obtain the cell lysate. The cell lysate along with the in-taken Flutax2-GMO-MENs was collected and measured for the fluorescence of Flutax-2 (using
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BioTek instruments, synergy HT) at λex = 496 nm and λem =524 nm to determine the
concentration. All the fluorescence measurements were recorded by subtracting the
corresponding controls to adjust the background fluorescence from the cellular
components. The protein content of the cell lysate was determined using Bio-Rad protein
assay kit (Braford method) by measuring the absorbance at 595 nm using a Cary 100 UVVIS spectrophotometer. As for the imaging studies, the cells were cultured on glass cover
slips (1 × 1 in2) pre-coated with the poly-L-Lysine (used as a cell adhesion promoter) in a
6-well cell culture plate at a density of 5 × 104 were cultured and let rested for about 10
minutes. Then, 2 ml of Cell medium was added along the walls of the wells. The cell
culture plate was incubated for 24 hours at 37° C. The cells were supplied with the fresh
cell medium that contained either of the four drug forms under study normalized to the
0.75 µM (1.76 µg/ml) of Flutax-2 concentration. The cell plate containing the Flutax-2GMO-MENs was kept under a 30-Oe magnetic field. The cell plates were incubated for
10 hours at 37° C. After the incubation process, cover slips were washed three times
with the PBS buffer and fixed with 4 % paraformaldehyde for 30 minutes followed by
washing thrice with the PBS buffer. The cover slips were mounted onto a glass slide
using a mounting medium (ProLong Gold Antifade Reagent). The excess mounting
medium was removed by placing a small piece of Whatman paper around the edges.
After the samples were dried for 2 hours, they were imaged through confocal microscopy
(TCS SP2, Leica Microsystems, Germany) at 488 nm (100%) illusion of an argon-ion
laser using 60X oil immersion objectives with a high numeric aperture and 1X confocal
electronic zoom settings to visualize cells.
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3.3. Results
Here, we conduct in-vitro studies on human ovarian carcinoma cell (SKOV-3) and
healthy ovarian cell (HOMEC) lines.

We demonstrate that high-specificity uptake of

PTX-loaded 30-nm CoFe2O4@BaTiO3 MENs could be triggered by a low-energy 30-Oe
d.c. external magnetic field with negligible heat dissipation. Through kinetics studies we
confirm that the drug penetrates through the tumor cell membrane and completely
eradicates the cells within a 24-hour period without affecting the surrounding healthy
cells. The procedures to fabricate the nanoparticles with different sets of coatings and
drug loadings are described in Section 4.2.2. The release threshold field, Hr, could be
controlled in a wide range, from 10 Oe to substantially over 200 Oe, through different
intermediate layers/coatings. A comparative analysis of the effect of the intermediate
layer type on Hr is summarized in Figure 36. By default, in order to provide adequate
coupling between the MENs and Flutax-2 (to provide the initial release field of the order
of 30 Oe), before being loaded with the drug, the MENs were coated with 3-Angstrom
thick glycerol monooleate (GMO) layers. The zeta-potential and size of the MENs,
GMO-MENs, HER2-GMO-MENs, and PTX-GMO-MENs are shown in Table 5. For the
purpose of a comparative analysis, we studied the following combinations of
nanoparticles: (i) MENs loaded with PTX, (2) MENs loaded with PTX and the popular
cancer biomarker HER-2 antibody, (3) free PTX, and (4) conventional MNs loaded with
PTX. As the conventional MNs, 30-nm magnetite nanoparticles were used.
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Table 5: The Malvern Zeta-sizer was used to measures size and Zeta-potential of the MENs, GMO-MENs,
HER2-GMO-MENs, and PTX-GMO-MENs (n=3). Concentration of the nanoparticles used for the
measurements was 500ug/ml of D.I water. Note: The measurements represented are the average of three
independent measurements.

Type of Particles
HER2-GMOGMO-MENs
MENs

Type of
measurement

MENs

Size (nm)

28.6 ± 7.5

30.9 ± 8.6

43.0 ± 3.6

44 ± 6.6

Zeta-Potential
(mV)

-45.0 ± 1.7

-41.6 ± 0.3

-26.3 ± 0.4

-40.7 ± 0.1

PTX-GMOMENs

3.3.1. Field-controlled drug release by MEN-based carriers
Drug release from these different MEN-based combinations was triggered by a magnetic
field at different strengths and frequencies, according to the physics described in our
earlier paper on the release of ARV drug AZTTP for treatment of HIV-1 virus in the
brain (1). The pellet obtained after the drug loading procedure was washed thrice with the
phosphate-buffered saline (PBS) buffer, to remove any residual unbounded drug. The
drug-loaded-MENs’ pellet was added to 1 ml of the PBS buffer in a vial and subjected to
a d.c. or a.c. magnetic field using a pair of Helmholtz coils connected to a d.c. or a.c.
power supply, respectively. After exposing the vial to any magnetic field environment
under study, the supernatant was obtained by spinning the sample at 3,000 rpm for 5
minutes and at 10° C. The supernatant was measured for the amount of the released drug
spectrophotometerically through the absorbance at the PTX maximum wavelength of 230
nm (131).
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A.

B.
Figure 23: Photo-absorption measurements of the release kinetics. (A) PTX drug release form GMO-MENs,
when treated at varying magnetic field strengths and frequencies after 1-minute treatment (n=3). (B) 3-D Chart
that illustrates the kinetics of the drug release. The data were measured spectrophotometrically as the
absorbance at 230 nm wavelength.
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Table 6: The field release dependence on the field, frequency, and the treatment duration. The table shows the
percentage of the field-triggered released PTX at different combinations of the magnetic field strength (12, 44,
and 66 Oe) and frequency (0, 100, and 1000 Hz) and the treatment duration (1, 5, 10, 60, and 120 minutes).

Field
Strength

Frequenc
y

12 Oe

0 Hz
100 Hz
1000 Hz
0 Hz
100 Hz
1000 Hz
0 Hz
100 Hz
1000 Hz

44 Oe
66 Oe

Percentage Paclitaxel Release at Different
Treatment Time Durations (Minutes)
1
6.1%
9.5%
10.7%
11.8%
11.2%
13.4%
29.1%
53.1%
78.1%

5
9.1%
12.8%
15.4%
18.3%
18.5%
30.4%
36%
62.9%
93.7%

10
10.3%
15.3%
22.6%
20.9%
41.3%
58.2%
38.4%
78.5%
98.5%

60
11.4%
20.5%
33.7%
22.2%
57.9%
73.2%
49.8%
92.3%
98.2%

120
11.1%
24.4%
56.7%
21.1%
66.2%
97.8%
50.5%
98.5%
98.2%

The results of the field-controlled drug release spectrophotometry (absorption)
experiments are summarized in Figure 23. Figure 23A shows the percentage of the drug
release after a 1-minute exposure to a magnetic field at three strengths, 12, 44, and 66 Oe,
respectively, for three different frequencies, 0, 100, and 1000 Hz, respectively. As
expected and previously explained, for each frequency, there was a critical field, Hr, at
which the drug release was significantly boosted. The increase of the frequency in the
range up to 1000 Hz under study increased the release efficacy (by over 40%) especially
at the low field range. Figure 23B illustrates the kinetics of the field-strength-frequency
dependence of the release for the five values of the field exposure times, 1, 5, 10, 60, and
120 minutes, respectively. The quantitative values are also presented in Table S1. For
every exposure time setting, a fresh solution with PTX-loaded GMO-coated MENs was
used. The field-triggered drug release was also confirmed through atomic force
microscopy (AFM), Fourier Transform Infra-Red (FTIR), mass spectrometry, and X-ray
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diffraction (XRD) pattern studies. The results are summarized in Figure 24, Figure 25,
Figure 26, and Figure 27 respectively

Figure 24: Atomic force microscopy. Topography and phase-contrast atomic force microscopy (AFM) images of
(A and B) GMO-MENs only, (C and D) GMO-MENs loaded with PTX, (E and F) GMO-MENs after the 36-Oe
1000-Hz field-triggered release, and (G and H) PTX only. The imaging was performed in Tapping Mode TM using
Nanoscope IIIa Multimode AFM (Veeco Metrology, CA). The samples were specially prepared for the imaging
by dispersing desired MENs on the silicon wafer surface (1 × 1 cm2). To achieve uniform dispersion of MENs,
the nanoparticles of choice were first mixed in chloroform solution (1mg of particles in 600 µl of chloroform).
Then, 100 µl of this solution was mixed with 200 µl of isopropanol and the solution was set to 3500-rpm
centrifugation for 3 minutes. Finally, the obtained pellet of MENs was dissolved in 200 µl of Chloroform and 20
µl of this solution was placed on a silicon wafer and then dried at room temperature overnight. The silicon wafer
containing the desired MENs were glued on to a metallic sample puck and mounted on the AFM stage. All the
images were performed in 256 × 256 scan resolution at a scan rate of 0.5 Hz at a 40-nm Z-scale and a 600-Phase
angle.
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Figure 25: Four transform infra-red studies. Fourier Transform Infra-Red (FTIR) results showing the spectrum
change at different stages of the drug release.

A.

B.

C.
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D.

E.
Figure 26: Mass spectroscopy results showing (A) the significant peak of PTX at 876 nm in the MBPS buffer, (B)
GMO-MENs in the MPBS buffer, (C) the significant peak of PTX at 876 nm when conjugated to the GMOMENs in the MPBS buffer, (D) PTX-GMO-MENs after the field treatment, (E) PTX after the release.

Figure 27: XRD pattern. XRD results of GMO-MENs at the three important phases of the release: (RED)
before and (GREEN) after binding with PTX before the release and (BLUE) after the field-triggered release.
Prior to performing the measurements, the nanoparticles were dispersed on a Silicon wafer and dried for 24
hours.
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3.3.2. Field-controlled drug uptake by tumor cells through the MEN-induced
nano-electroporation
Fluorescent cellular drug uptake experiments were performed on the SKOV-3 cells using
the four different drug forms under study, (i) free Flutax-2, (ii) Flutax-2 bound to the
conventional MNs, (iii) Flutax-2 bound to GMO-MENs, and (iv) Flutax-2 bound to HER2-GMO-MENs, respectively. The obtained Flutax-2 concentration was normalized to the
protein amount. The results of the experiment performed in triplicates are shown in
Figure 28. These results showed that the drug uptake increased by a factor of five for the
drug carried by field-controlled MENs compared to the drug driven by the HER-2
antibodies.

Figure 28: Drug uptake by cancer cells via different carriers. Comparison of four different forms of Flutax-2
drug intake by SKOV-3 cells (n=3).
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3.3.3. Confocal microscopy to visualize the internal drug localization in SKOV-3
cell lines
To visualize the internal localization of each of the four drug forms under study, (i) free
Flutax-2, (ii) Flutax-2-GMO-MENs, (iii) Flutax-2-HER-2, and (iv) Flutax-2-MNs,
respectively, in SKOV-3 cell lines, we conducted the following fluorescence imaging
experiments.

Figure 29: Confocal microscopy imaging of the drug uptake by SKOV-3 with different drug carriers. Confocal
microscopy image of SKOV-3 cells showing the sub-localization of Flutax-2 (drug) when bound to different
carrier systems: (a) free drug, (b) drug-HER-2, (c) drug-GMO-MNs in 30-Oe field. (d) drug-GMO-MENs with
no field, (e) drug-GMO-MENs in 30-Oe field. The scale bar is 47 µm.

3.3.4. Field dependence of drug uptake in cancer and healthy cells
To understand the field dependence of the described process, we performed the cellular
drug uptake experiments under a varying magnetic field strength on both cancer ovarian
(SKOV-3) and healthy ovarian cell (HOMEC) lines. The HOMEC cells were cultured
according to the same procedures that are described for the SKOV-3 cells in Section
Methods. As a control, the cells with GMO-MENs only (without Flutax-2) were treated
under the equivalent conditions. The cell culture plates with the MENs and drug-GMOMENs were exposed to three different field strengths, 5, 15, and 30 Oe, respectively. The
results are summarized in Figure 30. The measurements showed that, as the field was
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increased above approximately 30 Oe, the drug penetration into the cancer cells (SKOV3) greatly increased. On the other hand, it can be noted that the drug barely affected the
healthy cells (HOMEC) in the field range under study.

A.

B.
Figure 30: Field dependence of the drug uptake by SKOV-3 and HOMEC cells. Flutax-2 drug uptake by
HOMEC and SKOV-3 cells in varying magnetic fields (B). The drug uptake quantitatively presented in (A) was
measured by a fluoremeter (n=3). The scale bar on the images is 47 µm.
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3.3.5. Cancer cell viability test
After we confirmed that the drug-loaded MENs in the vicinity of the cancer cells indeed
acted, as a field-controlled valve to let the drug in (due to the effective nanoelectroporation effect according to our hypothesis), we studied the viability of the cancer
cells for different combinations of the drug and the carrier after the drug penetrated
through the cell membrane. (Here, maintaining the remote field at 30 Oe provided the
specificity to the cancer cells or, in other words, ensured that the healthy cells were
intact.) The summarizing images that were obtained in 24 hours after the penetration are
shown in Figure 31. The three key combinations of the carrier included (i) no particle, (ii)
HER-2-GMO-MENs (Note: Here, HER-2 stands for the HER-2 biomarker antibody), and
(iii) GMO-MENs, respectively. Accordingly, the three images (from left to right) in
Figure 31A show the morphology of the cancer cells after 24-hour treatment by (i) the
free drug (with no particle carrier), (ii) drug-HER-2-GMO-MENs with no field applied,
and (iii) drug-GMO-MENs in a 30-Oe d.c. field. The three control images in Figure 31B
show the morphology of the cancer cells after the 24-hour treatment by the same three
combinations of the carrier with no drug present. To account for the number of cells
viable after the 24-hour treatment, Trypan-Blue viability assay was performed. The
quantitative data of the cell viability tests are also summarized in Table 7.
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A.

B.

Figure 31: Confocal imaging of SKOV-3 cell viability after treatment by different drug-carrier combinations
with and without field. Confocal images of: (A) SKOV-3 Cells treated with PTX drug with different carrier
combinations, (left) no career with no field, (middle) HER2-GMO-MENs with no field, and (right) GMO-MENs
in a 30-Oe field and (B) SKOV-3 Cell Controls that include the same three carrier combinations with no PTX
drug present

Table 7: The table shows the percentage of cells viable after the 24-hour field-treatment period for different
PTX-MEN combinations and field treatment conditions (n=3).

Drug

Field (30 Oe)
-

-

+

+

Type of Treatment
Control-1
(No particle)
Control-2
(GMO-MENs-HER2)
Control-3
(GMO-MENs)

Percentage Cells Alive
99 ± 1 %
98 ± 1%
98.5 ± 0.7 %

-

FREE

86 ± 8.8%

-

GMO-MENS-HER2

71 ± 9.8%

+

GMO-MENS

31 ± 11.8%
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3.3.6. In-vitro Cytotoxicity Assay
To determine the cytotoxicity of the GMO-MENs on SKOV-3 cells, a quantitative
colorimetric XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium inner salt) assay was performed. The assay is based on the
reduction of XTT tetrazolium salt by the viable cells to form orange colored formazan
derivative. In this assay, 1×105 cells were seeded per well in a 96-well plate and
incubated at 37° C for 24 hours. After the incubation, the cell medium was replaced by
the medium containing the GMO-MENs at a differential concentration of 0- 100 µg/ml
per well and the cells were incubated for another 24-hour period. Then, the cell medium
was replaced with a fresh one and washed with the PBS buffer and cell viability assay
was performed by adding 50 µl per well of XTT-activated solution from the XTT test kit
supplied by ATCC and incubate for 4 hours at 37° C. The experiments were performed in
triplicates. As summarized in Figure 32, no significant cytotoxicity was observed.

Figure 32: XTT cytotoxicity assay. The chart shows the results of XTT Assay performed on SKOV-3 cells at
different concentrations of GMO-MENs (n=3).
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3.3.7. Heat-dissipation due to field-treatment with MENs
In this experiment, the temperature was measured locally via Infra-red (IR) camera FLIRi3 on the surface of both cancer (SKOV-3) and healthy (HOMEC) ovarian cells before
and after a field treatment, as shown in Figure 33. The experimental error of the setup
was approximately +/- 2 degree Celsius of the infrared camera. The magnetic field of 30
Oe was applied for a 24-hour period. No significant heat dissipation was observed, as a
result of the field treatment. The negligible heat dissipation (compared to the
conventional method) is a direct consequence of the intrinsic nature of the magnetoelectric coupling which resulted in the unprecedented high-efficacy control of intrinsic
electric fields by external magnetic fields.
A.	
  SKOV-‐3	
  before	
  and	
  after	
  H

B.	
  HOMEC	
  before	
  and	
  after	
  H

Figure 33: Dissipation-free physics. Surface temperature measured via Infra-red (IR) light for (A) cancerous
(SKOV-3) and (B) healthy (HOMEC) ovarian cells before and 100-Oe field treatment

83

3.4. Discussion
The results of the above experiments confirmed our hypothesis that MENs loaded with
the drug PTX could serve, as high-specificity remotely controlled (via magnetic fields)
delivery nanosystems to treat EOC. This function was achieved due to the localized
electroporation effects induced by the MENs in the vicinity of the cancer cell membranes
when exposed to an external magnetic field. The experiments were conducted to separate
the two core field-dependent processes according to the main hypothesis. These two
processes are defined by the following two critical fields, respectively: (i) the threshold
field, Hth, for MENs to penetrate through the cancer cell membrane to deliver the drug
into the cell cytosol (by means of the field-induced localized nano-electroporation effect
in the vicinity of MENs); and (ii) the release field, Hr, that triggers unloading of the drug
after the drug-loaded MENs penetrated into the cell. The specificity to the cancer cells
was defined not just by the typical HER-2 antibody chemistry, but also by the physical
mechanism that relied on the significant difference in the threshold field between the
healthy and cancer cells. This threshold field was measured to be of the order of 30 Oe
and above 200 Oe for the SKOV-3 and HOMEC cells, respectively. Moreover, these
experiments indicated that this remote-magnetic-field-triggered electric-field-defined
specificity to the cancer cells resulted in a more pronounced eradication of the cancerous
cells. The percentage of the cell-penetrated drug was increased by at least a factor of five
compared to the traditional antibody-mediated targeting (Figure 29). In addition, after the
drug was efficiently transferred through the tumor cell membrane by the field-controlled
MEN-initiated nano-electroporation, complete eradication of the cancer cells (without
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affecting the healthy cells) was observed within a 24-hour period of a low-energy 30-Oe
treatment (Figure 30 and Figure 31).

To achieve adequately high efficacy of the drug delivery, the value of the release field,
Hr, (~30 Oe) was chosen to be higher than the value of the threshold field to penetrate
through the membrane, Hth, (~10 Oe) for the cell of the same type. It can be reminded
that the release field is defined by the binding force between the MEN and the drug,
while the penetration threshold field, Hth, is mostly determined by the electric properties
of the cell membrane that lead to the localized electroporation effects. We could control
the release field by the proper selection of the intermediate layer between the drug and
the MEN. (As summarized in Figure 36, by choosing different intermediate layers we
could control the initial release field in a wide range, from less than 10 Oe to over 200
Oe. By default, a 2-nm thin GMO layer was used, as the intermediate layer.) In addition,
the release field depended on the field treatment duration and the frequency of the a.c.
field, as shown in Figure 23B. For example, as shown in Figure 23A, the
spectrophotometry measurements of the absorbance at 230 nm (for PTX) indicated that
only 1 minute of field treatment at a 66-Oe d.c. magnetic field was sufficient to release
over 95 % of the drug. As shown in Figure 23B, the same release efficacy (of over 95 %)
could be achieved also at a 1000-Hz a.c. field at smaller field strength of 44 Oe in 2 hours
of treatment. This complex dependence can be explained by the fact the external field
effectively reduces the energy barrier that holds together the MEN and the drug while an
increase of the treatment duration increases the temperature-induced probability to
overcome the barrier or, in other words, break the bond. As for the frequency
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dependence, in our previous paper we explained the underlying physics through field
torque effects that break the bond,, the frequency increases (1). Here, it can be mentioned
that although using a.c. external magnetic fields could indeed add another knob to control
the targeted delivery, in this study to focus on the proof of the main hypothesis, as
illustrated in Figure 18, we followed the d.c. field scenario. For example, a 3-angstrom
thin GMO as the intermediate layer resulted in the d.c. release field to be of the order of
30 Oe for the 24-hour treatment period. The d.c.-field-controlled drug release kinetics
was confirmed also through AFM, FTIR, and Mass Spectrometry, and X-ray diffraction
pattern studies, as shown in Figure 24, Figure 25, Figure 26, and Figure 27, respectively.
As confirmed by infrared measurements of the cellular surface temperature (Figure 33),
the MENs’s field action didn’t trigger any significant temperature changes in the field
and frequency range under study. This is in agreement with the fact that the MENsinduced delivery is an extremely energy-efficient process (because of the strong
quantum-mechanically determined magneto-electric coupling), which causes only
negligible heat dissipation.

3.5. Conclusion
As for the penetration threshold field, Hth, we found that for the cancer cell membrane the
value was of the order of 30 Oe, i.e. less than the d.c. release field (for the default MEN
carriers coated with GMO) of 60 Oe. Again, according to the main hypothesis, to ensure
the specificity to the cancer cells, it is important to maintain the remote field above the
release value for the tumor cells but lower than the threshold value for the healthy cells.
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Indeed, at a 30-Oe external d.c. field, the drug couldn’t penetrate through the healthy cell
membrane for the 24-hour treatment duration, which confirmed that the threshold field
for the drug-loaded MENs to penetrate into the healthy cell exceeded 30 Oe during the
entire treatment (Figure 30). Specifically, the GMO-MENs field-treated HOMEC cells
showed a negligible drug intake per 1 mg of the cellular protein content. The value was
0.18 ± 0.07, 0.30 ± 0.04, and 0.55 ± 0.16 % for the field strength of 5, 15, and 30 Oe,
respectively. On the contrary, SKOV-3 cells showed significantly higher values of the
drug intake, which was 1.50 ± 0.41, 2.36 ± 0.48, and 10.41 ± 1.54 % for the field strength
of 5, 15, and 30 Oe, respectively.
Least but not last, the cytotoxicity measurements with the standard XTT assay performed
on SKOV-3 cells at different concentration of MENs showed no significant toxicity even
at the highest nanoparticles concentration value of 100 µg/ml (Figure 32). The chart
shows the results of XTT Assay performed on SKOV-3 cells at different concentrations
of GMO-MENs.

Note: How to cite this chapter: The content of this chapter is published in my Nature
Scientific Reports article, hence please use this as a reference: Guduru, Rakesh, Ping
Liang, Carolyn Runowicz, Madhavan Nair, Venkata Atluri, and Sakhrat Khizroev.
"Magneto-electric Nanoparticles to Enable Field-controlled High-Specificity Drug
Delivery to Eradicate Ovarian Cancer Cells." Scientific reports 3 (2013).
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4. Chapter 4: Functionalized Magneto-electric Nanoparticles for Controlling the Drugreleasing Threshold Field
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4.1. Introduction
Over the last decade, nanomaterials have been widely used to deliver the therapeutics
drugs to the diseased tissue in order to increase the bioavailability and to reduce the toxic
side effects to the healthy tissues (132-134). Using surface modification to further tailor
important characteristics of the nanomaterials is a promising approach to develop future
applications in medicine, biology, and biotechnology (135-138). In the field of drug
delivery, surface-modification of nanomaterials plays a crucial role in determining drug
binding & release kinetics (139, 140). Commonly used surface-functionalizing agents to
coat nanomaterials include poly(lactic-co-glycolic acid) (PLGA), glycerol monooleate
(GMO),

Poly-L-Lysine,

Tween-20,

and

Ethyl-3-(3-dimethylaminopropyl)

-

carbodiimide (EDC) (141-145). Drug delivery and release using most of these surfacefunctionalized nanomaterials are typically governed by the change in pathological
conditions, such as pH, temperature, redox microenvironments, and enzymatic reactions
(146-149). Consequently, the capability to control the delivery and particularly release
processes in a wide range of properties suited for different applications remains an
important challenge. Alternatively, the recently introduced body-temperature magnetoelectric nanoparticles (MENs) exploit the magneto-electric (ME) effect to release the
therapeutic drug cargo without compromising the structural and functional integrity of
the drug at body temperature (1). The ME effect allows to use an external magnetic field
to remotely access the intrinsic electric fields that govern the binding forces between the
MEN’s surface and the drug load. The ability to remotely control this binding force
would be an important milestone in the development of nanostructures for controlled
targeted drug delivery and release. Previously, we have shown that there is a certain
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frequency-dependent threshold magnetic field for the drug to be released. (Thereafter we
refer to this field also, as the dissociation field.) This field is determined by the ionic
and/or covalent interaction between the two bonded entities or, in other words, by the
Coulomb’s forces between the oppositely charged MEN and the drug molecules in the
bond (polarized due to the chemical interaction). Therefore, this dissociation field can be
strongly influenced by a thin (~2 nm) intermediate layer, which changes the polarization
of the two entities. Therefore, we refer to this intermediate layer also, as the
functionalization layer. The important goal of the described study is to demonstrate how
tailoring the composition of the intermediate layer could be used to control the
dissociation field magnitude and frequency, specific for each application. Particularly,
experiments were developed to dissociate the drug molecules from the MENs’ surface at
the following three different ranges of the remote magnetic fields, (i) low (< 10 Oe), (ii)
moderate (100 Oe), and (iii) high (> 200 Oe), respectively, in a frequency range from 0 to
over 1000 Hz. These field ranges are relevant for many important applications, e.g.,
treatment of HIV in the brain, central nervous system (CNS) stimulation, deep-tissue
drug delivery for cancer treatment, magnetic imaging, and others. Further, the control via
the field frequency provides an additional knob particularly important for the release
process (1).

Introducing the intermediate functionalization layer will result in changing

the binding affinity between the drug and the MEN’s surface. One important requirement
to this layer is to maintain sufficiently strong binding with the MEN’s surface while keep
binding to the drug molecules relatively weak.

Accordingly, we implemented this

concept by choosing the following three intermediate layers, (i) Glycerol monooleate
(GMO), (ii) Tween-20, and (iii) Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC),
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respectively. In this study, we used Paclitaxel (PTX) as the model drug, as it is one of the
most widely used antineoplastic agents against ovarian, breast, neck, head and non-smallcell lung carcinoma, and others (120, 150, 151). We used CoFe2O4-BaTiO3 coreshell
MENs, as a drug delivery vehicle, due to their ability to exhibit magneto-electric effect at
body temperature (152, 153).
4.2. Experimental methods
4.2.1. MENs fabrication
CoFe2O4-BaTiO3 coreshell nanoparticles are fabricated according to the procedure
described in section 2.2.1

4.2.2. MENs surface functionalization
GMO-MENs were prepared by incubating 0.1 mg of GMO with 5 mg of MENs in 5 ml
of PBS (pH 7.4) buffer for 12 hrs. (Note: to achieve uniform surface modification, the
solution was slowly agitated during incubation). The solution was later subjected to
centrifugation at 20,000 rpm for 20 minutes at 10° C to remove excess GMO. The
obtained pellet was re-suspended in ethyl acetate: acetone (70:30) solution and recentrifuged three times to obtain GMO-MENs. Tween-20-MENs were prepared by
incubating 0.1 mg of Tween-20 with 5 mg of the MENs in 1 ml PBS (pH 7.4) buffer for 2
hrs. while agitating slowly. Later, the solution was centrifuged at 20,000 rpm for 20
minutes at 10° C to remove excess Tween-20. The previous step was repeated thrice to
obtain Tween-20-MENs. EDC-MENs were prepared by incubating 125 µl of EDC (conc.
1mg/ml in PBS) with 5 mg of the MENs in 5 ml of PBS (pH 7.4) buffer for 4 hrs. while
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agitating slowly. Later, the solution was centrifuged at 20,000 rpm for 20 minutes at 10°
C to remove excess EDC. The previous step was repeated thrice to obtain EDC-MENs.
Surface modified MENs were lyophilized and stored at 4° C until further use.
4.2.3. PTX drug loading
100 µg of PTX drug was added to 1 ml PBS (pH 7.4) buffer containing 1 mg of desired
nanoparticles (MENs, GMO-MENs, Tween-20-MENs, and EDC-MENs). The solution
was later incubated for 3 hrs. while agitating slowly at room temperature. After
incubation, the solution was centrifuged at 3000 rpm for 10 minutes at 10° C to collect
the pellet containing drug loaded nanoparticles. The separated supernatant was isolated
and measured for absorbance spectrophotometrically (Cary-100 UV-VIS) at 230 nm to
determine the unbounded drug (154). Figure 34 shows the PTX standard calibration plot
obtained by varying the drug amount (50 µg to 3.25 µg) in 1 ml of PBS buffer. The drugloading percentage was calculated using the below equation.
Drug  loading  (%) = total  amount  of  drug  added  –   amount  of  drug  in  the  supernatant ×100  

(2)

Figure 34: Paclitaxel drug calibration curve obtained using spectrophotometer. A) Absorption maxima at 230
nm for different drug concentration (50 µg/ml to 3.12 µg/ml) in PBS buffer. B) Linear dependence of 230 nm
absorption maxima with the drug concentration.
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4.2.4. Remote magnetic field triggered PTX drug release
The isolated pellet after drug loading was washed twice with the PBS (pH 7.4) buffer to
ensure the complete removal of the residual/unbounded drug. Then, the pellet was resuspended in 1 ml of PBS buffer and subjected to varying magnetic field strengths and
frequencies. The magnetic fields were generated using low-powered Helmholtz coils
connected to a d.c. power supply of 0 Hz and to an a.c. generator of 100 Hz and 1000 Hz.
After every single treatment, the solution was subjected to centrifugation at 3000 rpm for
3 minutes to separate the supernatant. This supernatant was used to measure the
absorbance spectrophometrically at 230nm to account for the amount of released drug.
(Note: the setup of the magnetic field treatment is shown in Figure 8)

4.2.5. SKOV-3 Cell culture
Human ovarian carcinoma cell lines (SKOV-3) were used to investigate the in vitro
cytotoxicity of the nanoparticles (MENs, GMO-MENs, Tween-20-MENs, and EDCMENs). SKOV-3 cells were purchased from American Type Culture Collection
(Manassas, Virginia). McCoy’s 5A medium (Life Technologies, NY) supplemented with
10% fetal bovine serum (Sigma-Alrich) and 1% penicillin-streptomycin (science-cell)
was used, as a cell culture medium. SKOV-3 cells were cultured in an incubator at 37° C
temperature, 5% CO2 and humidified atmosphere.
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4.2.6. In-vitro Cytotoxicity measurements
The cytotoxicity of the MENs, GMO-MENs, Tween-20-MENs, and EDC-MENs on
SKOV-3 cells was measured using a quantitative colorimetric XTT (sodium 2,3,-bis(2methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt)
assay (155). Briefly, approximately 0.1 million SKOV-3 cells were seeded per well in a
96-well cell culture plate along with a 100 µl of growth medium. Cell culture plate was
incubated for 24 hrs. at 37 ° C to reach confluency. Then, the growth medium was
replaced with the medium containing desired nanoparticles at varying concentration 0100 µg/ml per well and allowed to incubate for another 24 hrs. After 24 hr. incubation,
growth medium containing nanoparticles was removed and cells were washed with PBS
buffer twice to remove the dead cells. Now, 100 µl of the fresh medium along with a 50
µl of XTT-activated solution (from the XTT test kit supplied by ATCC) was added to
each well containing the cells and was returned to the incubator for 4 more hours. (Note:
XTT assay results presented were the average of three independent measurments).

4.2.7. MENs size and surface charge measurements
Size and surface charge measurements of the nanoparticles were performed using
Malvern Zetasizer (156). 0.5 mg of the desired nanoparticles (MENs, GMO-MENs,
Tween-20-MENs, and EDC-MENs) was dispersed in 1 ml of D.I water and this solution
was used to measure the size (in standard cuvette) and charge (in folded capillary cuvette).
(Note: The size and charge data presented in the results is the average of three
independent measurements).
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4.2.8. Sample preparation for FT-IR measurements
One drop (10 µl) of the desired nanoparticle solution (MENs, GMO-MENs, Tween-20MENs, and EDC-MENs) at concentration 1 mg/ml was taken on a pre-cleaned silicon
wafer and dried over night to measure the FT-IR spectrum. All the FT-IR measurements
were performed using JASCO-4100 instrument.

4.3. Results
4.3.1. MEN’s Intermediate (Functionalization) Layer
As mentioned above, in order to tailor the dissociation field magnitude and frequency
required to trigger the release of the bounded PTX from MENs in a specific application,
we coated the MENs’ surface with the following three intermediate layers, GMO, Tween20, and EDC, respectively, as shown in Figure 35. By its nature, Zeta-potential indirectly
reflects the binding affinity between a nanomaterial and the drug. The higher Zeta
potential implies the higher effective charge and therefore results in the higher Coulomb
interaction and the higher dissociation field. We measured the surface zeta-potential, size,
and Fourier Transform Infra-Red (FTIR) absorption spectrum of MENs before and after
functionalization to understand the effects of the selected surface modification. Indeed, as
summarized in Table 8, the results show a significant dependence of the zeta potential
values on the functionalized material (average of three independent measurements): -45.0
mV ± 1.72 for non-functionalized MENs, -41.6 mV ± 0.26 for GMO-MENs, -34.9 mV ±
0.20 for Tween-20-MEN, and -30.4 mV ± 0.81 for EDC-MENs. The results also indicate
a slight (~3%) increase in the average size (n=3) of MENs after coating with the
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functionalization layer: 28.6 nm ± 7.5 for MENs, 30.9 nm ± 8.9 for GMO modified
MENs, 29.5 nm ± 5.6 for Tween-20 modified MENs, and 31.1 nm ± 4.4 for EDCmodified MENs. FTIR spectrum of the GMO modified MENs surface (Figure 36B)
showed peaks at 1738 cm-1 and 2941 cm-1, which correspond to the ester bond, and CH2
stretching modes, respectively. The peaks indicate the presence of the GMO layer on the
MENs surface (143). The Tween-20 modified MEN’s surface (Figure 36C) showed FTIR
peaks at 1158 cm-1 and 2862 cm-1 that correspond to C-O ester bonds and C-H bonds,
respectively (157). Figure 36D shows FTIR spectral peaks of the EDC modified MENs at
2852 to 2921 cm-1 and 1460 cm-1, which correspond to a C-H alkanes stretch and amide
bonds, respectively (158).

Figure 35: SEM image showing of the MENs. A) Uncoated MENs, B) GMO-MENs C) Tween20-MENs, and D)
EDC-MENs. Scale bar 100nm.
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Table 8: Change in zeta-potential and size measurements of the MENs surface before and after surfacefunctionalization. Zeta-potential values are the average and standard deviation of three independent trails (n=3).

Functionalizing
agent

Size
[nm]

Zeta potential
[mV]

Uncoated-MENs

28.6 ± 7.5

-45.0 ± 1.72

GMO-MENs

30.9 ± 8.6

-41.6 ± 0.26

Tween-20-MENs

29.5 ± 5.6

-34.9 ± 0.20

EDC-MENs

31.1 ± 4.4

-30.4 ± 0.81

PTX-MENs

28.9 ± 7.7

-44.8 ± 1.67

PTX-GMOMENs

44 ± 6.6

-40.7 ± 0.1

PTX-Tween20MENs

32.3 ± 6.1

-31.1 ± 0.51

PTX-EDC-MENs

33.8 ± 3.2

-27.7 ± 1.3

Figure 36: FT-IR for surface functionalized MENs. MENs (A), GMO-MENs (B), Tween-20-MENs (C), and
EDC-MENs (D).
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4.3.2. PTX Drug Loading onto MENs surface
PTX drug loading onto differently functionalized MENs’ surfaces was achieved by
incubating the drug with the MENs in PBS buffer (pH 7.2). Time-dependent drugbinding kinetics was performed to determine the ideal incubation time to maximize the
drug loading percentage. The knowledge of the loading capability of the nano-carrier
type (MENs) is important for optimizing its drug delivery characteristics. Figure 37A
shows that ~16%, ~42%, ~91%, and ~77% of PTX binds to the uncoated MENs, GMOMENs, Tween20-MENs and EDC-MENs, respectively for 3 hrs. of incubation. The drug
loading percentage was determined by measuring the UV light absorption maxima at 230
nm in supernatant solution. Figure 34 shows the PTX absorption maxima at different
drug concentrations. To determine the binding efficacy of the PTX drug with different
MENs, we performed a binding isotherm study by varying the drug concentration from
25 µg/ml to 200 µg/ml per 1 mg of MENs. As shown in Figure 37B, the results indicate
the PTX binding efficacy was highest for EDC-MENs (79 µg to 86 µg) followed by
Tween20-MENs (55 µg to 58 µg), GMO-MENs (34 µg to 39 µg), and the uncoated
MENs (3 µg to 4 µg). To simulate the PTX binding efficacy in the human blood
circulatory system, we continuously circulated these particles for 2 hours using a
peristaltic pump at a flow rate of 8 ml/minute. The measured percentage of PTX (loaded
on MENs) that remained intact, as a result of the circulation experiment was 91.1% for
EDC-MENs, 87.0% for Tween-20-MENs, 79.5% for GMO-MENs and 58.4% for nonfunctionalized MENs.
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A.

B.

Figure 37: PTX drug loading. A) Time kinetic of PTX binding onto different MENs surface at 1:10 weight ratio
(0.1 mg of PTX and 1 mg of MENs). B) Binding isotherm of PTX onto different MENs surface at varying PTX
drug concentration and for 3 hrs. incubation time.

4.3.3. On-Demand Paclitaxel Release Using Remote Magnetic Fields
PTX bound to different functionalization layers (of MENs) was treated with d.c. and a.c.
magnetic fields to release the drug without affecting its functional and structural integrity,
according to the procedures described in detail in our previous publication (1). As shown
in Figure 38, the results indicated that the threshold magnetic field and frequency
required to trigger the release of over 70 % of the drug from the uncoated MENs were
approximately 10 Oe and 1000 Hz, respectively. . For GMO-MENs, the two values for
releasing over 97% of PTX became 100 Oe and 0 Hz, respectively. For Tween-20-MENs,
to release over 45% of the drug, the two values were 200 Oe and 1000 Hz, respectively,
while for EDC-MENs with the same field and frequency values we could release barely
above 5% of the drug. (Note: due to the limitation of our experimental setup, we could
not exceed the field and frequency values above 200 Oe and 1000 Hz, respectively.)
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Figure 38: Percentage PTX release at different magnetic field strengths and frequencies. A) Uncoated MENs, B)
GMO-MENs, C) Tween20-MENs, and EDC-MENs.

4.3.4. In-vitro Cytotoxicity
An in-vitro cytotoxicity study was performed using XTT assay to account for the
cytotoxic effects of the surface modified MENs on human ovarian cancer cells (SKOV3). As summarized in Figure 39, the results showed no significant toxicity on SKOV-3
cells when treated with MENs (~96% cells viable), GMO-MENs (~100% cells viable)
and Tween-20-MENs (~89% cell viable) at the highest concentration level of 50 µg/ml.
On the other hand, EDC-MENs showed relatively low toxicity (~77% cells viable) for the
same concentration.
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Figure 39: XTT cytotoxicity assay. Viability of the SKOV-3 cells was determined using XTT assay after treating
with various concentrations of MENs (uncoated MENs, GMO-MENs, Tween-20-MENs and EDC-MENs) for 48
hrs.

4.4. Discussion
Previously we have shown how low-energy external magnetic fields could increase the
bioavailability of the therapeutic drug cargo at the site of diseased tissue using the
magneto-electric nanoparticles, instead of the conventional magnetic nanoparticles
(MNs), as the delivery vehicle thereby overcoming the toxic side effects caused to
healthy tissue (1, 16, 159). One of the important advantages of using MEN-based
delivery is the fact that different remote magnetic field modes can be used for delivery
and release of the therapeutic payloads with unprecedented energy efficiency that
promises widespread application in the future. Exactly, as with the conventional MNs,
the drug delivery (navigation through the body) with MENs can be achieved by a d.c.
magnetic field gradient with a field magnitude in the range specific to the targeted region
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(superficial or deep-tissue). As for the release process, it cannot be achieved with the
conventional MNs and can be achieved with MENs via application of either low-energy
a.c. or relatively high d.c. fields. Therefore, unlike the conventional MNs, MENs offer a
new capability of field-controlled release. To enable high-efficacy independent control of
delivery (navigation) and/or release, MENs allow to separate the respective functions in
the magnetic field magnitude and frequency domains, as much as possible. Further, the
ability to vary the control fields in the widest possible ranges (in magnitude and
frequency domains) can significantly increase the range of potential applications for
MENs. For example, it is known that to target deep tissue carcinoma a relatively high d.c.
magnetic field (above 100 Oe) is required for the navigation. On the contrary, superficial
drug delivery can be achieved by field gradients with a d.c. field weaker than 100 Oe.
Further, the dependence of the release on the field frequency provides another powerful
control knob. For example, for GMO-MENs at a 1000-Hz frequency, less than 10 Oe
field was sufficient to achieve the same release percentage, as that achieved by the d.c.
field at a higher than 100 Oe magnitude. In the current study, we demonstrated how the
release fields could be varied in relatively wide magnitude and frequency ranges, from
below 10 to over 200 Oe and from 0 to over 1000 Hz, respectively, by choosing the
adequate intermediate (functionalization) layer between the MEN’s surface and the drug
molecules. Specifically, we studied the following three layer types, (i) GMO, (ii) Tween20, and (iii) EDC, respectively. As mentioned above, the navigation by MENs is similar
to the navigation by the conventional MNs while the field-controlled drug release is
specific to the MEN-based delivery only. Therefore, this study focused on the release
kinetics defined. Previously, we have shown that the MEN-triggered release depended on
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both the field’s magnitude and frequency. Particularly, we described a physical concept
according to which the d.c. field component was used for the navigation purpose (through
controlling spatial field gradients) while the a.c. field component was used for the
controlled drug release off the MEN-based carrier (1). The physics of the a.c. triggered
release was explained through the frequency-dependent spin-initiated torque. Indeed, our
results confirmed that increasing the frequency reduced the disassociation field Figure 5.
This trend was observed for all the three-functional layer types. The three materials
allowed to significantly increase the magnitude and frequency control ranges.

To control the value of the dissociation field, we varied the effective binding strength
between the MEN and the drug molecule (FMD). By introducing the intermediate
(functionalization) layer between the MEN and the drug molecule, it is important to
maintain the following inequality, FMI > FID, where FMI and FID stand for the binding
forces between the MEN and the intermediate layer and between the intermediate layer
and

the

drug

molecules,

respectively.

The

field-dependent

photo-absorption

measurements (Figure 5) indicated that the lowest and highest disassociation field
strength and frequency values for GMO and EDC functionalization layers, respectively,
with Tween-20 being in the middle. In fact, it should be mentioned that the full (100 %)
release could be easily achieved for GMO (with field strengths of less than 100 Oe even
at zero frequency), only 50% release could be achieved for Tween-20 and EDC with the
field strength and frequency ranges available in the current study (due to the equipment
limitations). In other words, a substantially higher threshold magnetic field (> 200 Oe at
zero frequency) is required to release over 50% of the PTX drug from either Tween-20-
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MENs or EDC-MENs. This observation correlates with the Zeta-potential measurements
that show the deviation of the Zeta potential for the functionalized MENs from the Zeta
potential of the non-functionalized MENs. The Zeta potentials values for Tween-20 and
EDC-coated MENs, -34.9 ± 0.20 mV and -30.4 ± 0.81 mV, respectively, are higher
compared to that for the non-functionalized MENs, -45.0 ± 1.72 mV, and GMO-coated
MENs, -41.6 ± 0.26 mV. The two latter combinations require only 10 and 100 Oe fields
to release approximately 70% and 97% of PTX, respectively.

One side effect of the surface functionalization is the effect on the drug loading
percentage and drug-binding efficacy (160-162). It is important to consider and if
possible take advantage of this effect when tailoring the properties to control the
dissociation field. This effect is reflected in our results (Figure 3). For example, the PTX
loading amount was increased by over 75 and 80% after MENs were functionalized with
Tween-20 and EDC, respectively, for a 3-hour incubation period, compared to that for the
non-functionalized MENs. These results were also consistent with the circulatory system
binding efficacy results, where EDC displayed over 91% drug intactness to the
nanoparticles (EDC-MENs) after circulating for 2 hours at 8 ml/minute, which is the
human coronary flow rate per minute per gram of the myocardium (163). Finally, the invitro cytotoxic experiment (Figure 39) indicated that neither of the nanoparticle types
(MENs, GMO-MENs, of Tween-20-MENs) displayed any detectable toxicity, as long as
the nanoparticle concentration was kept below 50 µg/ml. Moreover, GMO-MENs
displayed no toxicity at all (~100% cell viability) even at the highest concentration values
under study (above 100 µg/ml), indicating the true biocompatible nature of the GMO
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(164, 165). The EDC-MENs showed a slightly higher toxicity, i.e. only 77% cells were
viable after 48-hour treatment at 50 µg/ml concentration. By reducing the concentration
of EDC-MENs to 20 µg/ml we could increase the cell viability to over 90%. (Note: AFM
analysis, Mass spectroscopy analysis and XRD analysis of the drug release process is
presented in the supplementary file)

4.5. Conclusions
This study demonstrated the unique ability of the recently developed body-temperature
MENs-coated with intermediate (functionalization) layers, such as GMO, Tween-20, and
EDC to control the drug release threshold field in wide ranges both in magnitude and
frequency domains.

While relatively small fields (~10 Oe) might be enough for

navigating the drug in superficial body layers, relatively higher fields (>100 Oe) are
required for navigating the nanoparticles deep in the body. 30-nm CoFe2O4-BaTiO3
coreshell structures were used, as the MEN carriers. Using the described
functionalization layers could also increase the bioavailability of the drug, as they
provide higher binding efficacy and thus result in minimal drug loss before it reaches the
target. Because of the quantum-mechanically caused high-energy efficiency of the MENdriven delivery, MENs could also carry higher drug payloads compared to the
conventional MNs and release almost 100% of the drug on demand (via application of a
low-energy a.c. field) to the target tissue. Using a popular anti-cancer drug, Paclitaxel, we
demonstrated how to control the dissociation field for releasing drug from the MEN
carrier by choosing the right functionalization layer. Through a comprehensive set of
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experiments

including

FTIR,

photo-absorption,

XRD,

AFM,

zeta-potential

measurements, blood-circulation environment simulations, and in-vitro studies on
SKOV-3 cell lines, a release of the drug on-demand was achieved at the following three
different sub-ranges, (i) low (< 10 Oe), (ii) moderate (100 Oe), and (iii) high (> 200 Oe),
respectively, by selecting the three functionalization layers, GMO, Tween-20, and EDC,
respectively. Finally, the toxicity of the different MEN-functionalization layer
combinations was studied on SKOV-3 cell lines using XTT assay at the particle
concentration of 50 µg/ml, which resulted in the following percentages of viable cells: (i)
non-functionalized MENs: 96%, (ii) GMO-MENs: 100%, (iii) Tween-20-MENs: 89%,
(iii) EDC-MENs: 77%. In summary, these results suggest that the functionalization of
MENs paves a way for a substantially broader application of the new field-controlled
nanocarriers (MENs) in targeted drug delivery.

Note: How to cite this chapter: The content of this chapter is published in my Particle &
Particle System Characterization article, hence please use this as a reference: Rakesh
Guduru, Sakhrat Khizroev. “Magnetic Field-controlled Release of Paclitaxel Drug from
Functionalized Magneto-Electric Nanoparticles” Particle & Particle System (2013)
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5. Chapter 5:Magneto-electric Nanoparticles for Non-invasive Brain Stimulation
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5.1. Introduction
The signaling in a biological neural network is based on a highly collective system of
electric charges, neurotransmitters and action potentials. The ability to incite the neuronal
charge excitations from outside with the purpose to artificially stimulate the neural
network remotely (non-invasively) remains an important roadblock to enable leapfrog
advances in the important area of neuroscience and related applications in medicine and
neural engineering. A neural network can be considered, as a complex electric circuit
made of many neurons connected through synapses formed between axons and dendrites.
Both types are known, as chemical and electrical synapses, respectively, transfer
information between adjacent axons and dendrites directly or indirectly through electric
field energy. Consequently, the neural network is sensitive to external electric fields.
Moreover, the ability to efficiently control the network at micro- or even nano-scale can
enable unprecedented control of important brain functions. The underlying physics is still
an open question because of the many technical difficulties associated with direct studies
of the brain functions. The existing technology typically relies on invasive direct-contact
electrode techniques, such as Deep Brain Stimulation (DBS), which is one of only a few
neurosurgical methods allowed for blinded studies. Existing non-invasive brain
stimulation methods include repetitive transcranial magnetic stimulation (rTMS) (166,
167) and transcranial direct current stimulation (tDCS) (168, 169). rTMS and tDCS
represent major advances of the state of the art in noninvasive brain stimulation, but the
depth and locality focusing are limited in both methods (170). In rTMS, high intensity
magnetic fields are required to stimulate deep brain regions but high intensity magnetic
fields may lead to undesirable side effects (171). One potential solution to overcome the
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important roadblock for enabling non-invasive control of the neural network is to exploit
the new concept of using magneto-electric (ME) nanoparticles we propose. ME materials
represent a sub-group of multiferroic materials that are of great interest to the research
community because of their ability to couple magnetic and electric fields at room
temperature (172, 173). To our knowledge, our study for the first time describes the
application of ME nanoparticles to the area of brain stimulation. Particularly, our
approach relies on using ME nanoparticles to achieve the following important features for
noninvasive monitoring and stimulation the brain activities. First, using ME material
nanoparticles through temporarily injected aqueous solutions is the key enabler for
efficient coupling between magnetic and electric fields at nano- and/or micro-scale over
the entire brain volume. Particularly, remotely controlled magnetic fields, instead of
electric fields, can be used to induce strong local electric charge oscillations (in ME
nanoparticles) that can directly interact with the neural network and therefore be used for
localized and targeted brain stimulation (Refer Figure 40). Unlike surface-limited electric
fields that are typically generated by invasive contact electrodes, magnetic fields
generated by injected ME nanoparticles can effectively penetrate the entire brain
noninvasively, and be ‘‘switched’’ on and off remotely using external low-energy
magnetic field sources. The nanoparticles must satisfy certain requirements on the
strength of magneto-electric (ME) coupling (defined by the ME coefficient). Second,
magneto-electric nanoparticles must be smaller than approximately 20 nm in diameter to
penetrate the blood-brain barrier (BBB). Having the size of the ME nanoparticles within
the BBB-defined boundary enables adequate delivery of the nanoparticles into selected
brain regions. (There are many chemical and physical processes to synthesize ME
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nanoparticles with the required parameters. For instance, ion beam proximity lithography
(IBPL) is a physical method that can be used to fabricate nanoparticles with a wide range
of sizes, ranging from sub-10-nm to over 50 nm in diameter (174, 175). Third, only very
low intensity external magnetic field is required to stimulate brain activity at any depth in
the brain. The external magnetic field can be focused to act upon ME nanoparticles in any
particular region of the brain. The external magnetic field generates AC signals in ME
nanoparticles that are correlated with the frequency spectrum of the neural charge
activity, which in turn causes neurons in the region to fire at similar frequencies (Figure
40). For example, provided an adequately large ME coefficient, low-energy magnetic
coils can be used to trigger the required stimulation, as described below in more detail.

Figure 40: Illustration of MENs technology for deep brain stimulation
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5.2. Experimental methods
5.2.1. Simulation
Below we describe the foundation of the modeling approach we used to model the effects
of MENs (with their externally excited electric and magnetic moments) on the brain
activity. The computational procedure was built on top of a conventional model used to
simulate the electric field dynamics in the neural network. For example, see the article by
So et al to understand the underlying principles of the conventional model (176). To
account for the effect of ME nanoparticles, we made the following assumptions that can
be justified at this early stage of research. First, with the average diameter of the ME
nanoparticles below 20 nm in a neural system with the smallest feature size of at least an
order of magnitude higher, we can use a trivial point-dipole approximation to model the
electric field by each local nanoparticle (177). Second, we assume a uniform distribution
of nanoparticles in a brain region under study. The assumption is valid because the
nanoparticles, due to their sub-20-nm average diameters, experience a relatively
negligible resistance from the surrounding tissues and therefore their spatial distribution
in the ground state can be controlled by an external magnetic field. The electric dipole
moment of each nanoparticle, P, is determined by the external magnetic field, H,
according to the expression, 𝑃𝑃 =   

 𝛼𝛼   𝐻𝐻 ,

where 𝛼𝛼 is the 1st order linear magneto-

electric (ME) tensor coefficient. Therefore, assuming an isotropic matrix (with identical

diagonal coefficients and zero non-diagonal coefficients) with the typical value for 𝛼𝛼 of

100 V cm-1 Oe-1 and a local magnetic field of 300 Oe, the polarized moment at the

location of the nanoparticle would be 30 kV cm-1. In the current arrangement, the purpose
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of MENs is to act, as additional deep brain sources of electric fields that can be precisely
controlled by external magnetic fields because of the non-zero ME constant. The
nanoparticles can be considered, as finely controlled deep brain local stimulation
switches that can enable high-precision (with nanoscale localization) and high-throughput
(energy-efficient) noninvasive medical procedures. To artificially trigger (stimulate)
electric pulses in the brain region under study with the purpose to prevent or compensate
for any illness-caused malfunctions or lapses in a periodic chain of electric signals in the
parts of neural system occupied by the nanoparticles, we would apply a.c. magnetic fields
at the matching frequencies, as described below in more detail.

5.3. Results
In this study, we computed the effects of MENs at different concentrations and matching
frequencies to stimulate four different regions of the brain (healthy and Parkinson’s): The
four regions are: i) Thalamic, ii) Sub-thalamic (STN), iii) Globus pallidus external (GPe),
and iv) Globus pallidus internal (GPi). The computed typical periodic pulses in four
region of the healthy person’s brain are presented in Figure 41. It should be noted that the
healthy person’s brain signals are very periodic and uniform in amplitude whereas, the
signals in the individual with the Parkinson’s disease are more random and discrete
(Figure 42). Once optimized the simulation parameters, the results in four regions of the
Parkinson’s diseased brain using MENs procedure and using DBS procedure are shown
in Figure 43 and Figure 44 respectively.
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Figure 41: Typical electrical activity in four regions (thalamic, sub-thalamic, globus pallidus-external, and
globus-internal) of the brain in a healthy individual.

Figure 42: Discrete electrical activity in four regions (thalamic, sub-thalamic, globus pallidus-external, and
globus-internal) of the brain in an individual suffering from Parkinson’s.
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Figure 43: Restored-electrical activity in four regions (thalamic, sub-thalamic, globus pallidus-external, and
globus-internal) of a brain in an individual suffering from Parkinson’s after treating with MENs non-invasively.

Figure 44: Restored-electrical activity in four regions (thalamic, sub-thalamic, globus pallidus-external, and
globus-internal) of a brain in an individual suffering from Parkinson’s after treating with invasive DBS
treatment.
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5.4. Discussion
We studied the effects (on the potential recovery of the deteriorated electric field pulses)
of the injected MENs (in solutions) at different concentrations and stimulation
frequencies (generated by a 300-Oe external a.c. magnetic field source). The field
amplitude of 300 Oe was chosen from the requirement to maintain an energy-efficient
operation while keep MENs saturated during the procedure. The aqueous solution
concentration of the nanoparticles was varied from 0 to over 107 particles/cc while the
frequency was varied in the range of interest, i.e. from 0 to over 1 kHz. Within the ranges
of the modeling parameters, the optimum values for the nanoparticle concentration and
the magnetic field excitation frequency were found to be 3×106 particles/cc and 80 Hz,
respectively. Figure 41 illustrates typical periodic pulsed time sequences generated in the
four parts of the brain of a healthy person under normal conditions. It can be noted that
all the electric field pulses are quite periodic and uniform in amplitude. No lapses in the
periodic sequence can be detected. For comparison, Figure 42 illustrates typical signals in
the same four parts of the brain of the patient suffering from Parkinson’s disease. The
most drastic difference from the case of the healthy person is an appearance of
pronounced lapses in the periodic pulsed sequences particularly in the thalamic region.
Also, the periodicity of the pulses in the other regions is broken. Figure 43 illustrates the
four-pulsed sequences under study, as a result of the procedures with the optimized
stimulation parameters. It can be observed that the most dramatically damaged signals in
the thalamic region were fully recovered during the procedure. At least partial recovery
of the periodicity in the other three regions can also be observed. For comparison, the ME
nanoparticle stimulation still outperformed the invasive DBS procedure with electric
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signal stimulation. The ‘‘recovered’’ signals in the four regions of the brain during the
DBS procedure are shown in Figure 44. In this case, not only the periodicity was not fully
recovered, but also the amplitude of the signal in the STN region deteriorated compared
to the normal operation.

5.5. Conclusions
In conclusion, we modeled the effect of magneto-electric nanoparticles to non-invasively
stimulate the brain of a patient with Parkinson’s disease. Using the optimized values for
the concentration of the 20-nm nanoparticles (with the magneto- electric (ME) coefficient
of 100 V cm-1 Oe-1 in the aqueous solution) of 3×106 particles/cc and excitation
frequency of the externally applied 300-Oe magnetic field of 80 Hz, the pulsed sequences
of the electric field were brought to the levels comparable to those of healthy people. The
preliminary results of this study suggests that using ME nanoparticles can lead the way to
implementing nanotechnology to improve our understanding of the biological neural
network and develop new nano-medical methods for non-invasive monitoring,
preventing, and treatment of brain and other neural system diseases.

Note: How to cite this chapter: The content of this chapter is published in my PLoS one
article, hence please use this as a reference: Yue, Kun, Rakesh Guduru, Jeongmin Hong,
Ping Liang, Madhavan Nair, and Sakhrat Khizroev. "Magneto-electric nano-particles for
non-invasive brain stimulation." PloS one 7, no. 9 (2012): e44040.
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6. Chapter 6: Brain Activity Mapping Using Magneto-electric Nanoparticles Noninvasively
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6.1. Introduction
Ability to map the neuronal activity in the brain non-invasively is one of the greatest
scientific challenges of all time. Complete mapping of the neuronal activities in the brain
and correlating them to the behavioral or functional responses could help us in better
understanding of the brain’s function in different mental and behavioral states. Such an
understanding is the key to accurately diagnose and treat several neurological and
psychological disorders. Although, over the last two decades there have been numerous
attempts to accomplish the same using the invasive and noninvasive methods, the
complete theory of the brain’s function is poorly understood till date (178). Several
drawbacks of these current methods are discussed in detail in the previous section (1.6).
One potential solution to overcome these drawbacks for non-invasive mapping of the
neuronal activity in the brain is to exploit the use of magneto-electric property of MENs
(Nobel properties of the MENs are presented in the section 1.3.3). To our knowledge, the
use of MENs for monitoring the neuronal activity in the brain was never studied before.
To accomplish this, MENs (in aqueous solution) need to be intravenously injected
temporarily into the subject’s body. Using external magnetic fields these particles can be
distributed over the entire volume of the brain (39, 179). Once these particles are
distributed, the surrounding electrical conductivity of the brain tissue can influence the
surface charge of the MENs, which further affects the magnetic moment of the particles
(1). This change in magnetic moment can be recorded using MRI and MNI imaging
modalities (180), thus providing the electric field/conductive map over the entire brain
volume. This property of the MENs can also be exploited to track the neuronal activity
of the brain. For example, when neurons are fired, the surface charge distribution of the
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neuronal membrane will change, as a result of propagation of action potential (181), thus
affecting the magnetic moment of the MENs in their vicinity. Figure 45 shows the change
in the magnetic moment of the MENs (black to orange) in the vicinity of the neurons
where action potential (blue) is generated. Dependence of magnetic moment of the MENs
on surface charge is described in our previous publication (1).

Figure 45: Artistic view of the MENs interaction with neurons. The surface property of the MENs changes
under the influence of surroundings microenvironment thereby changing their magnetic moment.
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In this study, mathematical simulation results of MRI and MNI contrast dependence on
the surface charge, size, and concentration of the MENs are presented. (Note: for
comparison, contrast dependence of regular magnetic particles (MNs) is also presented).
Of all properties (i.e. charge, size, and concentration), our results indicated that the only
property that is influenced by the environmental conditions is the surface charge of the
MENs. Hence, we exploited this dependence to map the electrical activities of the brain.
The results showed a strong MRI signal in different regions of the brain based on the type
of activity it performs.

6.2. Experimental methods
6.2.1. Simulation of relative magnetization of nanoparticles
Field dependent relative magnetization of MENs and MNs can be simulated using
LANGEVIN function (L) shown in Equation 3 (182) where α is the relative
magnetization (Mrel). Equation 4 and Equation 7 were used to simulate the Mrel for MNs
and MENs respectively using a single particle model to study the effect of surface charge
and size (183). Equation 5 and Equation 8 were used to simulate the MMMF for MNs and
MENs respectively by expanding the single particle model to the bulk concentrations, i.e.
from the second order modified mean-field theory to study the effect of concentration of
the particle (183).
𝐿𝐿 𝛼𝛼 = coth 𝛼𝛼 −



(3)
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Magnetic nanoparticles:
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀, 𝑆𝑆𝑆𝑆𝑆𝑆     𝐻𝐻 =   𝜌𝜌  𝑀𝑀𝑀𝑀   𝐿𝐿
𝑀𝑀     (𝐻𝐻, 𝜌𝜌) =   𝜌𝜌𝑀𝑀   𝐿𝐿

𝐻𝐻 = 𝐻𝐻 +        𝜌𝜌𝑀𝑀   𝐿𝐿







     


Where,






   




     


Magneto-electric nanoparticles:
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Signal simulation for surface charge effect of the nanoparticle: To study the effect of the
surface charge of the nanoparticle on MRI/MNI signal intensity, the following parameters
were considered: nanoparticle size as 50 nm (for MEN and MN), magnetic saturation as
480000 A/m for magnetite, Magneto-electric coefficient (α) as 10,000 vm-1Oe-1 (for
MEN), Boltzmann constant (Kb) as 1.38× 10-23, temperature as 300K, permeability (𝜇𝜇𝜇𝜇)
as 4π× 10-7 H/m and surface charge as Q1 = 0.25 × 10-35 C, Q2 = 0.5 × 10-35 C, Q3 = 1 ×
10-35C, Q4 = 2 × 10-35 C, Q5 = 5 × 10-35 C (For MEN). Note: charge is not considered for
the MN as the relative magnetization is not affected by its charge on the surface.
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Signal simulation for the size effect of the nanoparticle: To study the effect of the size of
the nanoparticle on the MRI/MNI signal, the parameters were same, as above with the
change of size of the nanoparticles from 20 nm to 100 nm (for both MEN and MN) and
the surface charge for MEN was kept constant (0.25 × 10-35 C).
Signal simulation for the concentration effect of the nanoparticles: To study the effect of
the concentration of the nanoparticles on the MRI/MNI signal, the concentration of the
nanoparticles was varied from 0.05 mol/lit to 2 mol/lit. (i.e. C1 = 0.05, C2 = 0.1, C3 =
0.5, C4 = 2 mol/lit). The size and charge of the MENs were considered as 50 nm (same
for MNs) and 0.25 × 10-35 C, respectively.
6.2.2. MRI and MNI signal intensity simulations
The contrasting agent signal intensity in the MR imaging modality systems (i.e. signal
equation for two-dimensional spoiled gradient echo, 2DSPGR and three-dimensional
spoiled gradient echo, 3DSPGR) was generated based on the Equation 5 (180).
𝑆𝑆 = 𝑀𝑀







()( 
  

)

× exp −



∗

(6)

Where, SMRI= MRI signal, M is the magnetization of the contrasting agents, FA is the flip
angle, TR is the repetition time, T1 is the longitudinal relaxation time and T2*: is the
transverse relaxation time. For the particular concentration of the contrasting agents,
instrumental parameters, and the tissue types, the MRI signal S depends only on the
magnetization of the contrasting agents (SMRI α M). In case of MNI, the signal intensity is
only dependent on the magnetization of the contrasting agents and independent of
instrumental parameters and tissue type (SMNI = M). Thus, in both MRI and MNI,
magnetization of the contrasting agents plays a significant role in their signal intensities.
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6.2.3. Brain segmentation of the MRI data
The MRI head and the diffusion tensor image (DTI) data of the brain were obtained from
the 3D-Sclicer open source software database (184). Both images (i.e. MRI and DTI)
were co-registered using a Brainstorm, Matlab application software (185). The coregistered MRI data was segmented into white matter (WM), gray matter (GM),
cerebrospinal fluid (CSF), skull, and scalp using Brainsuite (version 13a) image analysis
software (185).
6.2.4. Tissue properties
All the segmented brain tissues were assumed to be isotropic (186), but the isotropic
conductivity values were set only for WM (0.14 S/m), GM (0.33 S/M), and CSF (1.79
S/m), as the nanoparticles in the scalp and skull region are absent at any given time point
(187). The electrical field values for these conductive tissues were calculated using the
equation 𝐸𝐸 =





where, E is the electrical field, 𝜎𝜎 is the conductivity and J is the current

density of the firing-neurons.

6.2.5. Tracking the neuronal activity of the brain
Intravenously injected aqueous solution of the MENs can be navigated to the brain and
uniformly distributed over the entire volume using an external magnetic gradient system
described elsewhere (41). Once the MENs are distributed over the entire brain, neuronal
activity can be tracked using MRI or MNI imaging modalities. To simulate this idea, we
segmented the MRI brain image based on the tissue type and the function it carries using
Brainsuite 13a software. Depending on the type of function brain performs, the neurons
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in the associated tissues change their surface properties thereby changing the relative
magnetization of the surrounding MENs.
6.3. Results
6.3.1. MRI/MNI signal simulation
In this study, we simulated the relative magnetization dependence on surface charge, size,
and the concentration of the contrasting agents (MENs and MNs) under varying magnetic
field (0 to 200 Oe).


The effect of surface charge of the nanoparticle

MRI/MNI signal simulation results show that increasing the surface charge of a particle
will increase the relative magnetization for magneto-electric nanoparticle (shown in
Figure 46), as magnetic moment of the MEN depends on the surface charge (Equation 7).
For magnetic nanoparticle, relative magnetization does not depend on the surface charge
(from Equation 4), as shown in Figure 47. To show the effect of surface charge on the
intensity of the MRI/MNI signal, relative magnetization at 50 Oe field was calculated
from the chart shown in Figure 46 for MENs. Note: for comparison MRI/MNI signal for
the MNs were also presented in Figure 47. These results indicate that increasing the
surface charge of the MENs from 0.25 × 10-35 C to 5 × 10-35 C increased the MRI/MNI
signal from ~0.44 to ~ 0.96, which is almost a 120% increase in the signal contrast.
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Figure 46: Relative magnetization curve showing the dependence on surface charge of the magneto-electric
nanoparticles.

Q1 Q2

Q3

Q4

Q5

Figure 47: Relative magnetization curve for MNs. The chart shows no change in the magnetization curve for
MNs having different surface charge (Q1, Q2, Q3, Q4, and Q5).
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Figure 48: Showing the corresponding MRI/MNI signal for Relative magnetization (Mrel) change for different
surface charge of the particle at H = 50 Oe. Mrel for magnetite (a-e). Mrel for MENs (f-j).



The effect of size of the nanoparticle

MRI/MNI single is also affected by the size of the nanoparticle (Equation 4 and 7). With
the increase in the size of the MEN from 20 nm to 100 nm, the relative magnetization of
the nanoparticle significantly decreased (Figure 49), whereas increase in size of the MN
decreases the relative magnetization (Figure 50). As a result, the MRI/MNI signal
intensity decreases from ~ 0.72 (for 20 nm) to ~ 0.01 (for 100 nm) for MEN (e through f
in Figure 51), and for MN it increases from ~ 11.5 (for 20 nm) to ~ 87.7 (for 100 nm) (a
through d in Figure 51).
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Figure 49: Relative Magnetization of the MEN for different particle sizes (d1=20nm, d2= 50nm, d3 = 75nm, d4=
100nm) keeping the charge Q as constant. (Note: that Magnetization decreases when size is decreases, as Q was
kept constant. In reality surface charge depends on the size of the particle).

Figure 50: Relative Magnetization of the MN for different particle sizes (d1= 20nm, d2 = 50nm, d3= 75nm, d4=
100nm).
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Figure 51: Showing the corresponding MRI/MPI signal for change in Relative magnetization (Mrel) at H = 50
Oe for different size particles. Mrel for magnetite (a-d). Mrel for MENs (e-f).



The effect of concentration of the nanoparticles

Increasing the concentration of the nanoparticles increases the relative magnetization of
both the type of nanoparticles (MENs and MNs) from the Equation 5 and 8 (Figure 52 for
MENs and Figure 53 for MNs). As a result, with the increase in the concentration of the
MENs from 0.1 to 2 mol/lit, the MRI/MNI signal increased from ~ 0.76 to ~ 0.98 (a
through d Figure 54) and for MNs the signal increased from ~ 0.26 to ~ 0.98 (e through f
Figure 54).
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Figure 52: Relative Magnetization of Magnetoelctric nanoparticles at different concentration (C1= 0.05 mol/lit,
C2 = 0.1 mol/lit, C3 = 0.5 mol/lit, C4 = 2 mol/lit).

Figure 53: Relative Magnetization of Magnetic Particle (Magnetite) at different concentration (C1= 0.05 mol/lit,
C2 = 0.1 mol/lit, C3 = 0.5 mol/lit, C4 = 2 mol/lit).
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Figure 54: Showing the corresponding MRI/MPI signal for change in Relative magnetization (Mrel) at H = 50
Oe for Concentrations. Mrel for magnetite (a-d). Mrel for MENs (e-f). (NOTE: (a,e at = 0.05 mol/lit
Concentration, b,f at = 0.1 mol/lit Concentration, c,g at = 0.5 mol/lit Concentration, d,h at = 3 mol/lit
Concentration ).

6.3.2. Brain segmentation
Figure 55 shows a segmented MRI head data based on the conductive properties of the
head.

Figure 55: Segmented MRI data. White matter (orange), gray matter (blue), CSF (red), skull (gray), and scalp
(brown).
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6.3.3. Electrical activity mapping
The electric field map was obtained for the neurons while firing with a current density of
~ 70 A/F (188) using the procedure described in the section 6.2.4. The results show the
isotropic electric field for WM is 5 V/cm-1, for GM is 2.1 V/cm-1, and for CSF is 0 V/cm1

. It should be noted that even though CSF exhibits higher conductivity (1.79 S/m), the

simulated electric field is 0 V/cm-1, as neurons are absent in the CSF. Figure 56 shows the
isotropic conductivity and electric field for different segments of the brain (assumption:
all the neurons in the brain tissue are fired simultaneously).

Figure 56: Isotropic electrical conductivity (A) and the electric field (B) map of the MRI segmented data.

6.3.4. Tracking the neuronal activity
Figure 57 show the neuronal activity of the brain in different regions based on the type of
activity it performs. Figure 57A shows the regular MRI image based on the tissue type
and the functions of the brain. Figure 57B through Figure 57E show the MRI image plus

131

the electrical field image depending on the activities performed by the brain. It should be
noted that by adding an additional signal generated solely by the change in the surface
charge of the MENs gives additional information corresponding to the neuronal activities
and further can be detected by the MRI/MNI imaging modality.

Figure 57: MRI image and electrical field image generated by using MENs as a contrasting agents. Images show
a clear additional signal (green) solely generated by the change in surface charge of the MENs due to the change
in membrane properties of the neurons during the propagation of the action potential.

6.4. Discussion
Figure 48 shows the MRI signal is strongly dependent on the surface charge of the
MENs, as the relative magnetization of the MENs is significantly affected by the charge
it carries (shown in Figure 46). Regular magnetic particle based contrasting agents do not
show this unique phenomenon (Figure 47). We exploited this unique feature of the MENs
to track the neuronal activity. The idea of using MENs for tracking neuronal activity is
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conceptualized in Figure 45. This figure clearly shows how MEN particle can change its
relative magnetization in the vicinity of the action potential in the neurons. The relative
magnetization is also affected by other properties, such as size and concentration of the
contrasting agents. But such properties will not be influenced by the changes in the
surrounding microenvironment and hence cannot be used, as contrasting agents for
studying the molecular compositions of the surroundings. Figure 57 (B through E) shows
the regular MRI signal (gray) image and an additional MRI signal (green) generated by
the MENs contrasting agent. For example, when the neurons in the frontal lobes are fired
(activities associated with the memory), the relative change in the magnetization of the
MENs contrasting agents in the vicinity of the fired neurons provide additional signals
shown in Figure 57B. Also, it should be noted that every activity (memory, vision,
movement, and etc.) in the brain is performed by bunch of neurons (a minimum of
50,000) in a synchronous alpha rhythm rather than by a randomly fired single neuron
(189). This property of the synchronous firing of neurons can further makes it possible to
visualize neuronal activities using MRI/MNI imaging modalities. Moreover, most of the
current MRI machines are capable of achieving close to microscale spatial resolutions
(190, 191). Therefore, tracking these microenvironmental changes using MRI imaging
modalities is fairly achievable. Using this approach one could track multiple activities
related to brain. In this study, we showed that activities associated with frontal lobes like
memory (Figure 57B), occipital lobes like vision (Figure 57D), parietal lobes like body
movements (Figure 57C), cerebellum like co-ordination (Figure 57F), and thalamus like
information process and relay (Figure 57E) can be tracked using MENs, as contrasting
agents.
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6.5. Conclusions
In conclusion, we modeled the effect of surface charge of the MENs on the MRI/MNI
signal intensities and compared it with the traditional contrasting agents. In this study we
also presented a new concept of using these MENs, as contrasting agents to track the
neuronal activity in the brain by MRI/MNI imaging modalities. The preliminary
computational results of this study showed that using MENs, as contrasting agents, one
could map neuronal activity independent of the origin (superficial or deep brain). This
non-invasive brain mapping could benefit in understanding brain functions thoroughly in
different mental and behavioral status, which is a key to treat several neurological
diseases.
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7. Chapter 7: Conclusions and Future Work
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7.1. Conclusions
The ability to control the intrinsic electric properties of the magneto-electric
nanoparticles using external magnetic field, provides several advantages to the fields of
medicine (therapy and diagnosis). This dissertation aims to pave a way disease-specific
medicine through a groundbreaking cross-disciplinary research in the fields of medicine,
nano-engineering and physics to demonstrate the novel capabilities of magneto-electric
nanoparticles (MENs) to enable unique mix of important functions, such as energyefficient and dissipation-free magnetic-field-controlled targeted drug delivery, ondemand release and high-specificity 3-D diagnostics. Specifically, MENs will be used for:
(i) in-vitro delivery/release studies on anti-HIV drug AZTTP and anti-Cancer drug
Paclitaxel, (ii) computational study on non-invasive targeted stimulation of CNS by lowenergy external magnetic field to treat Parkinson’s Disease, Alzheimer’s Disease, and
other dementia, (iii) computation study to map the neuronal activity using MENs, as a
highly sensitive MRI/MNI contrast agent.

Chapter 2 deals with the in vitro delivery/release study on anti-HIV drug AZTTP using
magneto-electric nanoparticles (MENs), as carriers. Although highly active anti-retroviral
therapy has resulted in remarkable decline in the morbidity and mortality in AIDS
patients, inadequately low delivery of anti-retroviral drugs across the blood-brain barrier
results in virus persistence. The capability of high-efficacy targeted drug delivery and ondemand release remains a formidable task. In this chapter we reported an in-vitro study to
demonstrate the on-demand release of azidothymidine 5’-triphosphat, an anti-HIV drug,
from 30-nm CoFe2O4@BaTiO3 magneto-electric nanoparticles by applying a low a.c.
magnetic field. Magneto-electric nanoparticles, as field-controlled drug carriers offer a
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unique capability of field-triggered release after crossing the blood-brain barrier. Due to
the intrinsic magnetoelectricity, these nanoparticles can couple external magnetic fields
with the electric forces in drug-carrier bonds to enable remotely controlled delivery
without exploiting heat. Functional and structural integrity of the drug after the release
was confirmed in in-vitro experiments with HIV-infected cells and through atomic force
microscopy, spectrophotometry, FTIR and mass spectrometry studies.

Chapter 3 extends the application of MENs drug delivery technology to delivery a most
widely used anti-cancer drug Paclitaxel (Taxol) for eradicating ovarian cancer cells. The
development of a technology capable of high-specificity targeted delivery of antineoplastic drugs would be a significant breakthrough in Cancer in general and Ovarian
Cancer in particular. We addressed this challenge through a nanotechnology that
exploited (i) the difference in the membrane electric properties between the tumor and
healthy cells and (ii) the capability of magneto-electric nanoparticles (MENs) to serve, as
nanosized converters of remote magnetic field energy into the MENs’ intrinsic electric
field energy. This capability allows to remotely control the electric fields within the cell
membranes and thus trigger high-specificity uptake of the drug through generation of
localized nano-electroporation sites in the tumor cells only. In in-vitro studies on human
ovarian carcinoma cell (SKOV-3) and healthy ovarian cell (HOMEC) lines, we triggered
high-specificity uptake of paclitaxel that was loaded on 30-nm CoFe2O4@BaTiO3 MENs
by a 30-Oe d.c. magnetic field.

The drug penetrated through the membrane and

completely eradicated the tumor cells within 24 hours without affecting the healthy cells.
The conclusions were supported by atomic force microscopy, Fourier-transform infra-red
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and X-ray diffraction analyses, mass spectrometry, surface temperature measurements,
and fluorescence imaging.

Chapter 4 involves in developing MENs technology for targeted drug delivery and ondemand field-controlled release can overcome the control challenges of the conventional
delivery approaches. The magneto-electric effect allows to use an external magnetic field
to remotely connect to the intrinsic electric fields that govern the binding forces between
the functionalized MENs’ surface and the drug load. Herein we report how tailoring the
composition of the intermediate functionalized layer can be used to control the threshold
magnetic field for the dissociation of the drug from 30-nm CoFe2O4-BaTiO3 coreshell
MENs in a controllably wide field range, from below 10 to over 200 Oe, as required for
enabling superficial, intermediate, and deep-tissue drug delivery. Paclitaxel is used, as the
model drug. Specific experiments are described to achieve controllable dissociation of the
drug molecules from the MENs’ surface at the following three different sub-ranges, (i)
low (< 10 Oe), (ii) moderate (100 Oe), and (iii) high (> 200 Oe), respectively, by
selecting the following 2-nm intermediate layers, (i) Glycerol monooleate (GMO), (ii)
Tween-20, and (iii) Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), respectively.
Toxicity study on SKOV-3 cell lines using XTT assay at the particle concentration of 50
µg/ml resulted in the following percentages of viable cells: (i) non-functionalized MENs:
96%, (ii) GMO-MENs: 100%, (iii) Tween-20-MENs: 89%, (iii) EDC-MENs: 77%. Fielddependent FTIR, fluorescence imaging, absorption spectra, atomic force microscopy,
magnetometry analysis, zeta-potential measurements, and blood circulation experiments
are used to study the described functionalization effects.
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Chapter 5 describes a computational study of using MENs to artificially stimulate the
neural activity deep in the brain. The new technology provides a unique way to couple
electric signals in the neural network to the magnetic dipoles in the nanoparticles with the
purpose to enable a non-invasive approach. Simulations of the effect of MENs for noninvasively stimulating the brain of a patient with Parkinson’s Disease to bring the pulsed
sequences of the electric field to the levels comparable to those of healthy people show
that the optimized values for the concentration of the 20-nm nanoparticles (with the
magneto-electric (ME) coefficient of 100 V cm-1 Oe-1 in the aqueous solution) is 3×106
particles/cc, and the frequency of the externally applied 300-Oe magnetic field is 80 Hz.

Chapter 6 presents a computational study of MENs for tracking the neuronal activities in
the brain using imaging modalities, such as MRI and MNI. In this chapter a unique
property of the MENs, i.e. magnetization dependence on its surface charge is computed
to account for the change in the MR/MN signal intensity. Based on this property we
computed the electric fields in different regions of the brain for the neuronal current
density of 70 pA/pF and found that the active regions of brain increases MRI signal by ~
30 % for 50 nm sized MENs with a ME coefficient 100 V cm-1 Oe-1 at the concentration
of 0.5 mol/L.

7.2. Future Work
The MENs based drug delivery/release of anti-HIV drug (AZTTP) will be further
evaluated in the in vivo HIV-infected monkey models (Rhesus macaque) at Yerkes
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National Primate Research Center of Emory University, Georgia. The MENs based drug
delivery/release of anti-cancer drug (Taxol) will be further evaluated in the in vivo
ovarian cancer mice model at animal care facility of Florida International University,
Florida. MENs technology for stimulating the neuronal activity will be further evaluated
in the in vivo Parkinson’s mice model at animal care facility of Florida International
University, Florida.
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